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BfR recommends provisional daily upper intake level and a guidance value for 
morphine in poppy seeds 
 
BfR Health Assessment No. 012/2006, 27 December 2005 
 
Poppy seeds are the mature seeds of opium poppy (Papaver somniferum L.). Because of 
their content of fatty oil and protein, they are used in the food sector in the manufacturing of 
bakery products and edible oil. Opium and its alkaloids can be obtained from the same plants 
from whose capsules the seeds are harvested. Opium is the name given to the dried milky 
sap which is obtained from the immature capsules. The most well known and most important 
opium alkaloid is morphine. Poppy seeds may also contain traces of alkaloids. 
 
In April 2005 BfR issued a warning about damage to health from poppy seeds in a press re-
lease. A mother had used an old home remedy and given her six-week-old baby strained 
milk from poppy seed to treat its sleep problems. The child was rushed to hospital with respi-
ratory disorders and impaired consciousness and treated there on suspicion of opiate intoxi-
cation. High levels of the alkaloids, morphine and codeine, were detected in its urine. In this 
context BfR pointed out that poppy seeds may contain varying amounts of morphine and 
codeine because of fluctuations in quality. Against this backdrop and following reports of the 
misuse of edible poppy seeds to produce drugs, BfR undertook a risk assessment of the oc-
currence of morphine in edible poppy seeds and issued an expert opinion on possible health 
risks for consumers. 
 
The data on which the assessment is based showed that the morphine levels in edible poppy 
seeds vary considerably and have obviously increased recently. Types of poppy, harvesting 
time and geographical origin could influence the levels. The main reason is probably con-
tamination of poppy seeds with alkaloid-containing capsule fragments and milky sap. The 
morphine levels could be drastically reduced by washing the seeds. Therefore, it is assumed 
that the elevated morphine levels in poppy seeds are linked to the recently introduced me-
chanical harvesting techniques in consequence of which the capsules are squashed. 
 
Morphine is mainly used to treat severe pain. Adverse reactions include nausea, vomiting, 
light headedness, respiratory depression and cardiovascular effects. Long-term use can lead 
to tolerance development as well as psychological and physical dependence. Individual sen-
sitivity varies markedly. This applies both to the desired effects and adverse reactions in me-
dicinal usage. In animal experiments morphine had a negative impact on development and 
reproduction. Mutagenic effects were also observed. The lowest therapeutic single dose for 
oral intake is 1.9 mg morphine. Doses of this kind can be ingested from normal portions of 
foods containing poppy seeds contaminated with morphine. They can then elicit the related 
spectrum of adverse reactions. This is shown, for instance, by studies from forensic medi-
cine. If a food contains larger amounts of poppy seeds from batches which have been con-
taminated to a high degree with morphine, morphine intakes may result in the worst case that 
are in the upper range of orally administered, therapeutic single doses or even higher. In 
cases like these, the risk of serious central nervous and peripheral effects like impaired con-
sciousness, respiratory depression and cardiovascular effects has to be assumed. 
 
It is clear that highly contaminated poppy seed batches of this kind are dangerous and not  
marketable. When, however, is the consumption of poppy seeds with lower morphine con-
centrations problematic in terms of health from the precautionary angle? In order to give offi-
cial food control authorities an instrument to answer this question, BfR has established a 
"provisional daily upper intake level" for morphine. It is 6.3 microgram morphine per kilogram 
body weight per day. It indicates the morphine intake which should not be exceeded during 
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one meal or several meals spread over the day. Taking into account the estimated portions, 
this leads to a provisional guidance value for poppy seeds of a maximum of 4 microgram 
morphine per gram. 
 
The Federal Institute for Risk Assessment calls on manufacturers to do everything in their 
power to reduce the levels of all pharmacologically active opium alkaloids in poppy seeds to 
the technically feasible minimum. BfR recommends that guidance values should also be es-
tablished on this basis for other alkaloids contained in opium poppy: codeine, noscapine, 
papaverine and thebaine. Until there has been a successful change in production conditions 
for poppy seeds, BfR advises against excessive consumption of foods with a high level of 
poppy seeds particularly during pregnancy. Poppy seed cakes, poppy seed containing de-
serts like certain sweet puddings (Mohnpielen) and special traditional dishes sprinkled with 
poppy seeds like yeast dumplings  (Dampfnudeln) may contain larger amounts of these 
seeds. 
 
1  Subject matter of the assessment 
 
The Federal Institute for Risk Assessment has expressed its opinion on the occurrence of 
morphine in edible poppy seeds and on limiting the morphine level of edible poppy seeds on 
health grounds. The regional authorities provided analytical data for this purpose. Based on 
these findings they had already voiced complaints about various batches of poppy seed 
samples on the grounds of elevated morphine levels pursuant to Article 14 paras 2a and 4 
Regulation (EC) No 178/2002. 
 
The current reason for assessment were media reports according to which by no means in-
significant amounts of morphine had been detected in edible poppy seeds. Drug addicts 
were, therefore, using them to produce drugs. Hence, scientists urgently recommended the 
establishment of maximum levels for the morphine content of edible poppy seeds. Given the 
need for action from the food toxicological angle, the predecessor institute to BfR, the Fed-
eral Institute for Consumer Health Protection and Veterinary Medicine (BgVV) had drawn 
attention to this for the first time in 2002. At that time it had recommended recording data on 
the alkaloid content of poppy seeds and examining whether there was a need to establish 
corresponding purity and quality criteria. 
 
2 Results 
 
Based on pharmacological data, BfR has established "a provisional daily upper intake level" 
for morphine in poppy seeds. It is 6.3 µg morphine/kg body weight/day and describes the 
intake which a person should not exceed (referred to kg body weight) during one meal or 
several meals spread over the day. Considdering the estimated portions, a provisional guid-
ance level for poppy seeds of 4 µg morphine/g was derived from the provisional daily upper 
intake level. Manufacturers are called on to do everything in their power to reduce the con-
tents of all pharmacologically active opium alkaloids in poppy seeds to the technologically 
feasible minimum. It is also recommended that guidance values should be established on 
this basis for codeine, noscapine, papaverine and thebaine. Therefor to the extent that the 
current data situation permits, provisional “orientation values” are indicated which would be 
acceptable from the health angle. Until there has been a successful change in the production 
conditions for poppy seeds, excessive consumption of foods with a high level of poppy seeds 
particularly during pregnancy is advised against. 
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3  Reasons 
 
3.1 Risk assessment 
 
3.1.1 Agent 
 
Poppy seeds (Semen Papaveris) are to be assessed for their content of pharmacologically 
active alkaloids. 
 
3.1.1.1 Poppy seeds and opium poppy – botanical origin, ingredients, use and cultivation 
 
Poppy seeds are the mature seeds of Papaver somniferum L. (opium poppy), which belong 
to the family of Papaveraceae. The seeds are various shades of black, white, blue or brown; 
they are between 0.9 and 1.5 mm long and are kidney shaped (1 - 7). 
 
Papaver somniferum is a crop plant and diverse varieties and sorts are cultivated. In princi-
ple, a distinction is made between the more primitive “shaken poppy” whose capsules open 
with pores and "closed poppy " obtained through cultivation whose capsules remain closed 
(1, 2, 6). The Mediterranean wild strain is regarded as a sub-species of Papaverum som-
niferum and is also termed Papaver somniferum L.ssp.setigerum (DC) Corb. (edible poppy) 
(12). Poppy seeds are used in the food sector to produce bakery products and edible oil (3 - 
7). The DAB 6 monograph "Semen Papaveris" (8) refers to the medicinal use of mature white 
poppy seeds. Poppy seed oil (Oleum papaveris) is also used for pharmaceutical and techno-
logical purposes (1). 
 
Papaver somniferum is grown all over the world and has the greatest economic importance 
in Asia. The plant is not only used to produce seeds and oil but also alkaloids and opium (1, 
2, 6). 
 
The milky sap (latex) of the immature capsules which is released by incisions and which has 
dried on the capsule surface is called opium. It contains approximately 20 - 25% alkaloids of 
which around 50 alkaloids have been isolated in pure form up to now. The main alkaloid of 
opium is morphine which is also present in the largest amount (12 %, depending on origin 7 - 
20%). Other important opium alkaloids are codeine (approximately 2%; 0.3 - 6%), thebaine 
(approximately 0.5%; 0.2 - 1%), noscapine (5%, 2 - 12%; formerly described as narcotine), 
narceine (approximately 0.5 %; 0.1 – 1.0%) and papaverine (approximately 1%; 0.5 - 3%) (1, 
9). 
 
The alkaloids are synthesised, stored and metabolised in the latex which is located in a 
closely woven network of mutually anastomosal laticiferous tubes. With the exception of the 
seeds, which are the only organ without milky sap, (11) it permeates all parts of the plant and 
is to be found in particular in the pericarp of the capsule (7, 9, 10). Varying amounts of the 
alkaloids have been detected in all parts of the plant. Differing alkaloid levels for the seeds 
have been indicated in the standard literature, which vary by several orders of magnitude. 
For instance, alkaloid concentrations have been reported in the trace range of    < 0.0001% 
(9) as well as values of 0.005% (11) or  0.009% (1, 2) and 0.01% (3, 7). In the relevant litera-
ture codeine, thebaine, noscapine, papaverine, rhoeadine, the papaver rubines B, C, D, E 
and morphine are indicated as alkaloids which occur in very small amounts in the seeds (1, 
2). However, some older reference works describe the seeds as being "free of morphine" (3, 
7) (for further details see 3.1.1.3). 
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Higher alkaloid levels can be found in other parts of Papaver somniferum, which are de-
scribed as drugs and/or used to harvest alkaloids. Fructus papaveris (poppy capsules with-
out seeds) are specified in mature or immature stage in various national pharmacopoeia. The 
drugs contain the same active substances as opium but at a far higher dilution. Their mor-
phine level fluctuates and is indicated as being between 0.12 and 0.89% (1, 2) or higher (7). 
What are more relevant for this assessment are possible indications that there may be a cor-
relation between capsule form and seed colour on the one hand and morphine level on the 
other (1, 2). For instance, capsules of white or light seeds produced lower morphine yields 
than blue- or dark-seeded capsules. Maturation investigations led to varying results which 
means that the most morphine was found in the stadium of half ripeness and, in other cases, 
in the mature capsules (1, 2, 7). Mention should also be made of Stramentum papaveris 
(poppy straw), which contains mature deseeded capsules (morphine level: 0.015 up to 
0.018%) (1, 2, 7) and Radix papaveris (poppy roots). They were shown to have approxi-
mately 0.03% morphine (7). 
 
The total alkaloid content of the plant, which depends on various factors (variety or sort, loca-
tion, soil conditions, climate, weather, harvesting time), increases in the case of Papaver 
somniferum during growth up to the flowering period and then falls again (1, 11). The alkaloid 
content also shows daily fluctuations with a minimum around lunchtime and a maximum in 
the early hours of the morning. There may be a particularly marked drop in content when the 
alkaloids are washed out from the mature capsules by rain or dew (1). 
 
In Europe (e.g. Austria and Germany) low morphine varieties of Papaver somniferum are 
authorised for cultivation. They are exclusively destined for the production of seeds which are 
used to manufacture bakery goods and oil. According to information from the Austrian 
Agency for Health and Food Safety/Institute for Seeds, Vienna (6) these seeds scarcely con-
tain any alkaloids and no morphine. They encompass for instance the only variety "Przemko" 
authorised in Germany and the varieties "Edel-Weiß", "Edel-Rot", "Florian", "Josef", "Zero" 
and "Zero 2000" authorised in Austria (6). 
 
Furthermore, in Europe, including the former Soviet Union, Papaver somniferum is mainly 
cultivated for direct alkaloid harvesting from capsules and poppy straw and parallel oil collec-
tion (1, 2). The cultivation of Papaver somniferum for opium production is limited, in accor-
dance with the UN protocol from 1953, to Bulgaria, Greece, Iran, India, the former Soviet 
Union, former Yugoslavia and Turkey. Furthermore, there is illegal cultivation for the pur-
poses of narcotics production (1, 2, 10). 
 
3.1.1.2 Statutory provisions 
The cultivation of Papaver somniferum L. requires an exemption in the Federal Republic of 
Germany pursuant to the Narcotics Act (BtMG) of 28 July 1981 § 3. It has only been granted 
for the low morphine opium poppy variety "Przemko" (cf. 3.1.1.1). 
 
Annex 3 to § 1 para1 BtMG, which lists marketable and prescription narcotics, includes Pa-
paver somniferum (plants and parts of plants), opium (the curdled sap of the plants which 
belong to the species Papaver somniferum), morphine and codeine. However seeds of the 
plants belonging to the species Papaver somniferum (including the sub-species setigerum) 
are explicitly excluded. 
 
Annex 2 to § 1 para 1 BtMG, which lists marketable, non-prescription narcotics, indicates 
thebaine.  
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Maximum values for the contents of opium alkaloids in poppy seeds are only known from 
Hungary (35). They indicate 30 µg/g for morphine, 20 µg/g for noscapine, 40 µg/g for mor-
phine and noscapine, 20 µg/g for thebaine and 20 µg/g for codeine. 
 
3.1.1.3 Analytical data on poppy seeds 
Aside from the occurrence of alkaloids (cf. 3.1.1.1), poppy seeds contain 40 - 60% fatty oil 
whereby the white seeds contain more oil than the blue or grey ones. Poppy seed oil has the 
following composition of fatty acids: 62% linoleic acid, 30% oleic acid, 5% palmitic acid, 3% 
stearic acid. Furthermore poppy seeds contain 15 - 24% proteins, the enzymes diastase, 
emulsin and lipase, between 0.25 and 1 % lecithin and around 3% pentosane as sugar. 
 
It is noted that the measurement data given below (Tables 1 - 6) were obtained using differ-
ent, non-standardised extraction and analytical methods and are, therefore, only comparable 
to a limited degree. 
 
3.1.1.3.1 Poppy seeds for sale in the German retail food trade 
Data on the alkaloid content of poppy seeds in the German retail food trade were initially only 
available to BfR from forensics. Alkaloid concentrations in poppy seeds had been determined 
in studies investigating the association between the consumption of bakery goods containing 
poppy seeds and positive results in urine, blood and serum, saliva and hair analyses for opi-
ates and the resulting problems for drug screening or doping controls (13, 14, 15, 22). 
 
Table 1: Morphine levels and country of origin of poppy seeds which had been sold in the 
German retail food trade according to Thevis et al. (13). 
 
 
Sample 
No. 
Tradename/ Com-
position 
Outlet Origin Morphine level (µg/g) 
1 Neuform® Health food store Denmark 8.4
2 Neuform® Health food store Hungary 6.9
3 Müller´s Mühle® Supermarket unknown 151.6
4 Insula® Supermarket unknown 2.1
5 FJD® Supermarket unknown 4.1
6 Rapunzel® Health food store Turkey 0.8
7 Davert® Health food store Turkey 0.9
8 Backmischung Bakery unknown 0.6
 
After enzymatic hydrolysis and liquid-liquid extraction by GC-MS, Thevis et al. (13) examined 
8 products for their morphine level. In 5 samples it was between 0.5 µg/g and 5 µg/g, in 2 
samples between 5 and 10 µg/g and in only one case 151.6 µg/g. The authors indicate that 
the high morphine content in sample no. 3 was confirmed by analysing a second package 
from the same batch, whereas other batches from the same manufacturer were only found to 
have low morphine concentrations of 1.1 µg/g. Furthermore, the authors note that all sam-
ples contained negligible amounts of codeine as well. 
 
Trafkowski et al. (15) analysed 11 samples (7 unmixed poppy seeds and 4 baking mixtures) 
from the Bonn region using HPLC-MS/MS for their contents of codeine, morphine, noscapine 
and papaverine (5 g sample was extracted by ultrasound in 10 ml buffer, determination limits 
were only given for detection in body fluids. For urine analyses for codeine, morphine, no-
scapine and papaverine they were 5.5, 12.38, 1.56 and 0.33 ng/ml respectively. Three times 
the detection limit was taken for the determination limit.) 
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Table 2: Alkaloid levels in poppy seeds and poppy seed-containing products which had been 
purchased in the Bonn region, excerpt from Trafkowski et al. (15). 
 
 
 Concentration in poppy seed (µg/g) 
No. Product Codeine Morphine Noscapine Papaverine 
1  Blaumohn Fa. ATCO 7.69 87.45 0.13 0.043
2  Blaumohn Fa. Neuform positive 0.00 0.00 0.000
3  Blaumohn Fa. Back-
stube 
1.06 3.34 1.42 0.057
4  Blaumohn Fa. Märsch 
Import 
0.82 3.65 1.57 0.057
5  Blaumohn Fa. Müller´s 
Mühle 
16.00 60.60 0.14 0.043
6  Blaumohn Fa. Davert 1.08 3.78 0.50 0.053
7  Blaumohn Rio Bravo 6.02 18.30 0.13 0.043
8  Mohn-Back Fa. 
Schwartau 
0.29 2.61 0.00 0.000
9  Mohn-Fix Fa. Pichard-
Dekor 
0.27 2.69 0.00 0.000
10  Mohn Füllung Fa. Gold 
Puder 
2.99 14.37 0.12 0.032
11  Mohn-Fix Fa. Backstu-
be 
0.22 1.51 0.08 0.000
 
The morphine contents in 7 samples were between 0 and 4 µg/g and between 14 and 87.5 
µg/g for the other 4 samples. The codeine levels only exceeded 1.1 µg/g in the case of the 
four last samples for which they ranged between 3 and 15 µg/g. Two other samples were 
noticeable which had a noscapine level between 1.4 and 1,6 µg/g whereas the levels of no-
scapine in the other samples were between 0 and 0.50 µg/g. The papaverine concentrations 
in all samples fluctuated between 0 and 0.06 µg/g. It is noticeable that neither morphine, no-
scapine nor papaverine could be detected in one sample of blue poppy seeds. Codeine 
could be detected but the value was obviously below the determination level.  
 
Furthermore, findings by Andresen and Schmoldt (22) should be mentioned. They analysed 
two batches of poppy seeds following extraction by ethanol using GC/MS. The first batch 
from Australia contained larger amounts of morphine (207 µg/g) and codeine (5.5 µg/g). In 
the second batch from Asia far lower levels of alkaloids were detected: 0.6 µg morphine/g 
and no codeine. 
 
Finally, measurement results on codeine and morphine levels in 48 poppy seed samples 
were recently made available by the Bavarian Regional Office for Health and Food Safety 
(LGL) which are given in Table 3. Measurements were taken using HPLC/DAD and secured 
using LC/MS/MS. 
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Table 3: Morphine and codeine levels in poppy seeds obtained in Bavaria 
   (n.n. = below the detection limit) 
 
Sample 
No. 
Origin if known Morphine (μg/g) Codeine (μg/g) 
1  65 6.4 
2  74 11.8 
3  8 n.n. 
4  66 8.6 
5  10 n.n. 
6  4 n.n. 
7 Czech Republic 201 23.7 
8  70 9.0 
9  96 9.6 
10 Russia (?) 4 n.n. 
11 Turkey 5 n.n. 
12 Denmark 25 2.0 
13  90 7.1 
14  98 9.8 
15  7 n.n. 
16  4 n.n. 
17  8 n.n. 
18  29 n.n. 
19  46 n.n. 
20  228 13,8 
21  17 n.n. 
22  8 n.n. 
23  198 27.6 
24 Turkey 3.10 1.80 
25  35.40 2.60 
26  95.50 14.00 
27  7.30 n.n. 
28  52.40 3.80 
29  53.60 2.80 
30  318.30 8.60 
31  79.80 12.70 
32  31.50 1.00 
33 Czech Republic 30.60 n.n. 
34  16.00 3.20 
35  67.60 10.90 
36  4.50 n.n. 
37  34.90 n.n. 
38  13.80 n.n. 
39  60.80 7.20 
40  78.90 12.20 
41  77.60 14.10 
42  64.50 5.10 
43  9.10 n.n. 
44  320.70 10.00 
45  330.00 10.30 
46  285.30  
47  203.20  
48  319.30  
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Of the 48 samples which mainly consisted of blue poppy seeds, only 13 had a morphine level 
≤ 10 µg/g. Codeine was detected in one of these samples at a concentration of 1.8 µg/g but 
was not detectable in the other 12. In 10 out of 48 samples the morphine level was between 
> 10 µg/g and ≤ 50 µg/g with codeine levels of maximum 3.2 µg/g or below the detection limit 
(no information available on the level). 16 samples showed morphine levels between > 50 
and ≤ 100 µg/g together with codeine levels up to maximum 14.1 µg/g. In the remaining 9 
samples morphine levels were measured between > 100 µg/g and maximum 330 µg/g which 
were coupled with codeine values up to maximum 27.6 µg/g. It is clear that rising levels of 
morphine in the seeds are often coupled with elevated codeine values. Since the country of 
origin of the poppy seeds was only indicated in a few cases, no associations could be estab-
lished between the alkaloid contents and geographical origin. It is noticeable that the poppy 
seeds of one manufacturer (sample nos. 3, 5, 17, 21, 22, 36, 38, 43) only contained relatively 
low morphine levels (8 samples: ≤ 17 µg/g, of which 6 samples: ≤ 10 µg/g). However, this 
could not be confirmed in other investigations (cf. Table 1, sample no. 3, and Table 2, prod-
uct no. 5). This means that it might be by chance that several samples from the same or 
similar origin (e.g. same batch, same harvest) could have been investigated with, therefore, 
similar alkaloid contents. This might also be the reason why almost all (12 our of 13) blue 
poppy seed samples from another manufacturer (sample nos. 1, 2, 4, 9, 13, 14, 28, 29, 31, 
35, 39 and 42) had morphine values between 50 and 100 µg/g and a high proportion (7 out 
of 10) of samples from a third manufacturer of blue poppy seed (sample nos. 19, 20, 30, 40, 
44, 45, 46, 47 and 48) had morphine values over 200 µg/g. Tracing the origin of poppy seeds 
from specific manufacturers might produce evidence of the causes of the low or high mor-
phine concentrations in the poppy seeds. It is also interesting that the analyses of poppy 
seeds of the low morphine species "Przemko" by the official Bavarian food control authority, 
which had been cultivated in 2004 by the Regional Agency for Plant Cultivation in Forchheim, 
(Baden-Württemberg), revealed a morphine content of 3.5 µg/g and codeine was not de-
tected. 
 
Furthermore, the analytical data on one product of baking poppy seeds (0.1% morphine, 
0.003% codeine) on sale in Germany should be mentioned. Their improper use as a milk 
extract recently led to severe health disorders in a six week old baby. It must be pointed out 
that the indicated morphine level of 0.1% (= 1000 µg/g) clearly exceeded the morphine levels 
(cf. Tables 1 - 5) given for poppy seeds up to now and verification is recommended. 
 
Overall, the analytical data situation on poppy seeds on sale in Germany must be described 
as very sparse as sample investigations are only available from a few regions in Germany 
and they are orientational in character. In almost all cases there are no details of batch num-
ber, country of origin, harvest years or botanical origin (cultivated types of opium poppy). 
Furthermore, apart from morphine it was mainly only codeine that was determined while data 
on the other relevant opium alkaloids are missing. 
 
Finally, the findings of the Chemical and Veterinary Investigation Office (CVUA) Stuttgart 
should be mentioned. They determined 210 µg morphine/g and 39 µg codeine/g using LC-
MS/MS in blue poppy seeds from one manufacturer and 120 µg morphine/g and 19 µg co-
deine/g in a poppy seed sugar mixture probably made from it. Consumption of the mixture 
had led to symptoms of disease in one patient.  
 
3.1.1.3.2 Poppy seeds sold in the international retail food trade 
The variations which occur in the alkaloid content of various poppy seeds and poppy seed-
containing products are presented in more detail in a table prepared by Rochholz et al. (5) 
using a literature search. It also lists the values for poppy seeds on sale in Germany men-
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tioned above (13) in the bottom row. Otherwise, it refers to samples collected around the 
world and is presented here in abbreviated form (Table 4) (5, 13, e.g. 16 - 21, 23). In some of 
the original works quoted (17, 21) a distinction is made for morphine and codeine contents 
between the "free" portion (dissolved from dust, capsule fragments and latex sticking to the 
outside of the seeds and from inside the seeds) and "bound" portion (released e.g. after acid 
hydrolysis). This is not included in the table. 
 
Table 4: Alkaloid levels in various batches of poppy seeds and poppy seed-containing baking 
mixtures, according to Rochholz et al. (5).  
 
Type of poppy seed Morphine [µg/g] Codeine [µg/g] Other alkaloids [µg/g] 
White poppy seeds 450   
Black poppy seeds 30   
Blue poppy seeds 2.6 - 107   
White poppy seeds 51.6 – 60.4   
Unknown 107 - 164 17.7 – 31.8 Thebaine: 8.2 – 20.7 
Blue poppy seeds, baking 
poppy seeds 
< 0.1 - 620 Codeine Thebaine 
Unknown 169 17  
Unknown 5.1 - 106 0.1 – 3.8 Thebaine: 0.3 - 14 
Papaverine: 0 – 3.6 
Poppy seed filling in bakery 
goods 
24 0.36 Thebaine: 0.46 
Papaverine: 0.05 
Unknown 4 - 200   
Blue poppy seeds 0.5 - 15 0.1 - 3  
White poppy seeds 13 1.5  
Black poppy seeds 17 - 294 3 - 14  
White poppy seeds 58.4 – 62.2 28.4 – 54.1  
Blue poppy seeds, white 
poppy seeds 
0.1 – 11.9 0.1 – 0.7  
Unknown 39 – 167 1.8 - 44 Thebaine: 1 - 41 
Papaverine: 0.17 - 67 
Noscapine: 0.84 - 230 
Unknown 2 – 251 0.4 – 57.1  
Poppy seed filling in bakery 
goods 
17.4 – 18.6 2.3 – 2.5  
Blue-black poppy seeds 0.964 0.79  
Unknown 0.6 – 151.6 low  
 
According to these international data, maximum contents of 620 µg/g morphine, 57.1 µg/g 
codeine, 230 µg/g noscapine, 67 µg/g papaverine and 41 µg/g thebaine were measured in 
poppy seeds. No associations could be determined between the colour of the poppy seeds 
and alkaloid occurrence. 
 
Table 5 gives the internationally published morphine contents of poppy seeds together with 
geographical origin. Table 5 can be seen as a supplement to Table 1. It contains data pub-
lished by Möller et al. (24). Some of the samples listed in Table 5 are also to be found in Ta-
ble 4. 
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Table 5: Morphine levels and countries of origin of poppy seeds which are sold in the retail 
food trade in various countries (supplement to Table 1) 
 
No.  Outlet Origin Morphine 
content (µg/g)
9 Unknown Australia 108
10 Unknown Unknown 73.2
11 Unknown Turkey 8
12 Unknown Australia 200
13 Unknown Hungary 44
14 Unknown Spain 60
15 Unknown Netherlands 5
16 Unknown Poland 12
17 Bakery Unknown 74
18 Unknown Unknown 175
19 Unknown Australia 120
20 Unknown Hungary 12
21 Unknown Denmark 10
22 Unknown USA 4
23 Import busi-
ness 
Netherlands 100
24 Import busi-
ness 
Eastern Europe 39
25 Import busi-
ness 
Eastern Europe 151
26 Import busi-
ness 
Eastern Europe 67
27 Health food 
store 
Denmark 2
28 Unknown Turkey 0.5
29 Unknown Hungary 1
30 Unknown Unknown 58
31 Supermarket India 167
32 Supermarket India 39
33 Unknown Australia 90
34 Unknown Hungary 46
35 Unknown Czech Republic 2
36 Unknown Spain 251
37 Unknown Turkey 5
38 Unknown Turkey 27
39 Unknown Netherlands 4
40 Retail trade 
Portland, Ore-
gon 
Unknown 294
41 Unknown Singapore 58 – 62
 
 
Even if one looks at all the data presented, the low number of samples per country of origin 
and the variability of findings do not permit the establishment of a clear association between 
morphine levels and country of origin. It is, however, noticeable that all four seed samples 
from Australia have high morphine levels (≥ 90 µg/g, Table 5) (cf. also 15, 16, 18, 22). Of the 
eight samples listed from Turkey, 27 µg morphine/g is the highest value (Tables 1, 3, 5). In 
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the case of the four Danish samples the highest value measured was 25 µg morphine/g (Ta-
bles 1, 3, 5). 
 
Of the 5 Hungarian poppy seed samples (Tables 1 and 5), 2 do not comply with the Hungar-
ian provisions (cf. 3.1.1.2) and show morphine levels above 30 µg/g. 
 
Table 6 below is taken from the recently published work by Rochholz et al. (30). It lists the 
samples, most of which are included in the preceding tables, by decreasing morphine levels. 
The finding described above is confirmed: the 9 Australian samples all have high morphine 
levels between 72 and 206 µg/g. 
 
Table 6: Morphine levels and countries of origin of poppy seeds which were on sale in the retail 
food trade in various countries, listed by decreasing content.     
 
Origin Morphine µg/g Origin Morphine 
µg/g 
Unknown 620 Netherlands 39 
Unknown 450 Eastern Europe 39 
Unknown 294 Unknown 33.2 
Spain 251 Unknown 30 
Australia 206 Unknown 29.5 
Australia 200 Unknown 28 
Unknown 175 Turkey 27 
Unknown 169 Netherlands 19 
India 167 Unknown 17 
Unknown 164 Czech Republic 13.2 
Unknown 151.6 Poland 12 
Eastern Europe 151 Hungary 12 
Australia 120 Denmark 10 
Australia 114.3 Denmark 8.4 
Australia 108 Turkey 8 
Australia 107 Unknown 7.3 
Unknown 107 Hungary 6.9 
Australia 106 Turkey 5.1 
Netherlands 100 Netherlands 5 
Australia 90 Turkey 5 
Unknown 85.5 Unknown 4.5 
Unknown 84.5 Unknown 4.1 
Unknown 74 Unknown 4 
Unknown 73.2 Netherlands 4 
Australia 72.4 Poland 2.7 
Unknown 69.3 Unknown 2.6 
Eastern Europe 67 Unknown 2.1 
Unknown 63 Denmark 2 
Unknown 62.2 Czech Republic 2 
Unknown 60.4 Unknown 1.1 
Spain 60 Hungary 1 
Unknown 58.4 Turkey 0.9 
Unknown 58 Turkey 0.8 
Unknown 51.6 Turkey 0.66 
Hungary 46 Asia 0.6 
Hungary 44 Turkey 0.5 
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3.1.1.4 Possible causes of high alkaloid levels in poppy seeds 
The reasons given for the, in some cases, high opiate contents of poppy seeds include the 
choice of less suitable botanical varieties (6), inopportune harvesting time (15, 22) and spe-
cific geographical origin (3.1.1.3.2). The contamination of poppy seeds with alkaloid-
containing capsule fragments and latex seems to be another fundamental problem which 
could probably be solved by using less aggressive harvesting methods and/or cleaning pro-
cedures. For instance Rochholz et al. (5) believe that the poppy seeds themselves only con-
tain very low levels of morphine and codeine and that these alkaloids only adhere as external 
contamination to the poppy seeds. They base this on findings that the morphine content of 
seeds could be drastically reduced through washing (e.g. 17, 22). For instance, Bjerver et al. 
(31) showed that 40 % of the total morphine content of blue poppy seeds could be removed 
by washing with slightly acidic water. The assumption by Andresen and Schmoldt (22) is dis-
cussed that the current elevated morphine levels in poppy seeds could be linked to a new 
machine harvesting technology introduced in recent years. This involves the squashing of the 
poppy seed capsules whereby the seeds are contaminated with the alkaloid-containing milky 
sap. The presence in particular of immature capsules has a detrimental effect (30). Accord-
ing to Andresen and Schmoldt (22), this procedure must be extended to include the careful 
washing of the seeds as the next step. The mechanical harvesting technique is used espe-
cially for "closed poppy" whose seed capsules remain closed even after ripening (cf. 3.1.1.1). 
In this way higher harvest yields are obtained than in the case of "shaken poppy" in which 
the seed capsules are emptied by hand or mechanically. Möller et al. (24) observed that the 
harvesting method used in low wage countries whereby the capsules are still cut open 
manually and the seeds collected in a container, leads to a lower contamination of the seeds 
with the milky sap. 
 
There is no discussion in the literature whether the fact that poppy seeds are obtained from 
capsules, which had previously been scratched to obtain opium (3), could be a cause of the 
alkaloid contamination of the seeds. It may be that these seeds are primarily used to produce 
poppy seed oil (12) which is deemed to be free of alkaloids (7). In principle, the parallel use 
of opium poppy plants to harvest alkaloids and opium on the one hand (with the requirement 
of high alkaloid biosynthesis) and to harvest low alkaloid seeds on the other (for which low 
alkaloid varieties seem to be more suitable) implies contradictory preconditions when it 
comes to choosing species and varieties.  
 
3.1.2 Hazard potential 
 
3.1.2.1 Opium alkaloids and opium as medicinal products 
 
In the following the pharmacokinetic and pharmacological data of the relevant opium alka-
loids and opium known from their pharmaceutical application are summarized. In the case of 
the companion alkaloids and opium this information can only be orientational in character. 
 
3.1.2.1.1 Morphine 
The phenanthrene alkaloid morphine ((5R, 6S, 9R,13S,14R)-4,5-Epoxy-N-methyl-7-
morphinen-3,6-diol, molecular weight (MW): 285.3, CAS No.: 57-27-2) is the main action 
component of opium. It is used for medicinal purposes as morphine sulphate pentahydrate 
(MW: 758.8; CAS No.: 6211-15-0) or as morphine hydrochloride trihydrate (CAS No.: 6055-
06-7, MW: 375.8) (10, 39, 40). 
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3.1.2.1.1.1 Applications and dosage 
Morphine is mainly administered via the oral or parenteral routes to treat severe and extreme 
pain (e.g. carcinoma pain). Furthermore, it is used as a hypnotic drug primarily when pain is 
the cause of insomnia. To alleviate dyspnoea morphine is administered in relatively low 
doses (38). At very high doses it can be used as an anaesthetic. The doses normally rec-
ommended for pain therapy in oral pharmaceutical forms are given in Table 7 below (42). 
 
Table 7: Recommended single and total daily doses for orally administered morphine (42) 
 
Age (body weight) Single dose Total daily dose 
Children up to the age of 2 
(up to 12.5 kg) 
Up to 2.5 mg morphine hydrochlo-
ride equivalent to up to 
1.9 mg morphine 
Up to 22.5 mg morphine hydro-
chloride equivalent to up to  
17.1 mg morphine 
Children aged between 2 - 6  
(up to 12.5 - 20 kg) 
2.5 - 5 mg morphine hydrochloride 
equivalent to 
1.9 – 3.8 mg morphine 
15 - 30 mg morphine hydrochlo-
ride equivalent to  
11.4 – 22.8 mg morphine 
Children aged between 6 -
12 
(20 - 40 kg) 
5 – 10 mg morphine hydrochloride 
equivalent to  
3.8 – 7.6 mg morphine 
30 - 60 mg morphine hydrochlo-
ride equivalent to 
22.8 – 45.6 mg morphine 
Adolescents 12 - 16 years 
(40 - 50 kg) 
10 – 20 mg morphine hydrochloride 
equivalent to  
7.6 – 15.2 mg morphine 
60 - 120 mg morphine hydro-
chloride equivalent to 
45.6 – 91.1 mg morphine 
Adolescents over the age of 
16 and adults 
10 – 60 mg morphine hydrochloride 
equivalent to 
7.6 – 45.6 mg morphine 
360 mg morphine hydrochloride 
equivalent to 
273.3 mg morphine 
 
The maximum effect can already be achieved 30 minutes after oral administration. The effect 
of a single dose lasts as a rule for 4 - 6 hours (38, 42). In the case of morphine sulphate pen-
tahydrate, 2.5 mg (equivalent to 1.9 mg morphine) were mentioned in the literature as the 
lowest oral therapeutic single dose to treat cancer pain or dyspnoea in adults (39). Patients 
more advanced in years (as a rule over 75) may be more sensitive to morphine (1, 38, 39, 
42). The dose must also be reduced in the case of hepatic insufficiency (1). In principle, a 
large variation in individual sensitivity to morphine can be assumed in the case of therapeuti-
cally desired effects and side effects (42, 44). The scientific literature points out the difficulty 
of establishing a standard dose for morphine. Rather a dose range of 2.5 – 2500 mg (usually 
however below 100 mg) is given for oral pain therapy with morphine sulphate pentahydrate 
as the single dose to be administered every four hours (39). An effect is, however, only to be 
expected from low doses in the case of opium alkaloid-naive patients who have not devel-
oped tolerance from prior treatment with opium alkaloids (cf. 3.1.2.1.1.4) (39). 
 
In their publication Carbajal and Simon (47) indicate for morphine an initial daily dose of 0.5 
up to 1 mg/kg body weight/day as the lowest oral therapeutic dose for sedation and analge-
sia for children. It is divided into 6 individual doses, i.e. 0.083 up to 0.17 mg/kg/body weight. 
If the dose is not effective, it can be increased by 50 %. Histamine release, hypotonia and 
obstipation are indicated as the side effects of this dose (cf. 3.1.2.1.1.2). The dosage infor-
mation does not refer to a specific children's age (47). It is assumed that the pharmacokinet-
ics of morphine in children are similar to those of adults (39). However, neonates are the 
exception; because of their immature P-450 system and reduced renal clearance, they have 
a longer half-life for morphine. Furthermore, the immature blood-brain barrier can lead in 
their case to elevated morphine concentrations in the brain. Neonates already developed 
cramps (48, 49, 39) at morphine doses (referred to kg bodyweight) which are otherwise rou-
tinely given to children. Attention is drawn to an elevated sensitivity of neonates vis a vis res-
piratory depression (39). 
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3.1.2.1.1.2 Pharmacodynamics 
For opioids (agonists and antagonists with morphine-like activity including natural and syn-
thetic opioid peptides) there are three types of receptors in human beings. Morphine has high 
affinity to the µ-receptor as an agonistic ligand. Of the endogenous opioids the endorphins 
(endogenous opioids) are widespread in the organism and involved in controlling various 
body functions. The animal organism also contains endogenous morphine and codeine bio-
synthesised from L-tyrosine, however, only in traces; their physiological relevance is un-
known. Activation of the µ-receptors leads to analgesia, mainly on the supraspinal (above the 
bone marrow) level, euphoria, dependence, miosis, respiratory depression, cough calming 
and obstipation (10, 32, 45, 46). 
 
Central effects 
 
Morphine has an analgesic effect by targeting various levels of the central nervous system 
(CNS). In addition to supraspinal there are also spinal points of attack. By increasing the re-
lease of dopamine in the nucleus accumbens, morphine creates an unrealistic feeling of well-
being (euphoria). In this way, it reduces fear in conjunction with acute pain (anxiolysis). Peo-
ple suffering from chronic pain do not benefit from these positive mental side effects but they 
are not at risk of becoming dependent. The tranquillising, sedative-hypnotic effect can also 
be used for pain therapy. There are reports of light-headedness, impaired consciousness 
and mood swings in the case of pain patients and healthy individuals after being given mor-
phine. Miosis (pupil constriction) is an indication of the taking of µ-receptor-agonistic opioids. 
Respiratory depression triggered by morphine can be observed in healthy test persons in a 
less developed form already at therapeutic standard doses but not, however, in patients suf-
fering from severe pain. In this case pain stimulates respiration and counters the morphine 
effect. The reduction in respiratory rate caused by higher doses of morphine can initially be 
compensated consciously. In the case of a further increase in dose, periodic respiration oc-
curs and finally respiratory arrest. As morphine dampens the reflectory excitability of the 
cough centre in the medulla oblongata, it has an antitussive effect. The nausea and vomiting 
frequently induced by morphine also result from its effect on the medulla oblongata. How-
ever, they are temporary and disappear after repeated administration. In the case of bedrid-
den patients, morphine does not influence blood pressure. In the case of standing patients it 
does lead to a drop in blood pressure at therapeutic doses because of peripheral vasodilata-
tion, reduced peripheral resistance and inhibition of the baroreceptor reflex. A low grade bra-
dycardia (cardioinhibition) may occur. At high doses morphine can trigger cramps. Central 
effects also include inhibition of the secretion of releasing hormones by the hypothalamus 
which regulate the pituitary gland. Effects on the hypophyseal-hypothalamic axis may lead to 
changes in the hormone status of corticoids, sexual hormones, prolactin and the antidiuretic 
hormone. Consequently, corresponding manifestations or clinical symptoms are possible. 
Finally, a drop in temperature and muscle rigidity (32, 38, 42, 48) can be mentioned as pos-
sible further consequences of central points of attack of morphine. 
 
Peripheral effects 
 
Morphine increases the tone of the gastrointestinal tract and reduces motility with the conse-
quence of spastic obstipation. Stomach motility is already reduced at relatively low doses of 
morphine. As a consequence of the contraction of the pylorus as well, the chyme only leaves 
the stomach slowly. In the ileum there is, in addition to increased tone, an inhibition of peri-
stalsis. Colon peristalsis is slowed down and the defacation reflex is suppressed. Morphine 
leads to a contraction of the gall bladder musculature and the sphincter oddi which leads to 
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bile congestion. Therapeutic doses of morphine can increase the tone and amplitude of ure-
thral contraction. Morphine leads to spasms of the bladder sphincter and inhibits the miction 
(bladder emptying) reflex. This means that, after administration of therapeutic doses of mor-
phine, urinary retention may occur and catheterisation may be necessary. Therapeutic mor-
phine doses can lead to a widening of blood vessels in the skin. Frequently, there is flushing 
of the face, neck and thorax which, in some cases, can also be attributed to histamine re-
lease. Furthermore pruritus (itching skin) can occur. In asthmatics bronchoconstriction may 
occur as a consequence of histamine release. From in vitro and animal studies different ef-
fects of morphine are reported on components of the immune system; however their clinical 
relevance cannot be assessed at the present time (32, 38, 42). 
3.1.2.1.1.2.1 Morphine effects in healthy test persons 
 
In the literature it is pointed out that the effects of morphine in healthy test persons may devi-
ate in some cases from those in pain patients. The predominant symptoms in healthy, pain-
free individuals given therapeutic doses are nausea and retching. Furthermore, there are 
symptoms of light-headedness, dizziness, difficulty in carrying out intellectual activities, apa-
thy and reduced physical activity. Only at higher doses do subjective analgesic and toxic 
effects increasingly occur, including respiratory depression (38).  
 
There are reports that one single administration of an opioid to a healthy opioid-naive test 
person leads to central nervous suppression and in psychomotor and cognitive tests to in-
creased reaction time and impairment of motoric co-ordination, of short-term and longer last-
ing attentiveness as well as of short-term memory (51). However, no corresponding dose-
response data following oral administration are available. A threshold dose upwards of which 
the onset of psychomotor impairment is to be expected following single oral administration of 
morphine is not known, but is relevant for safety in road traffic and at the workplace. In order 
to determine this threshold dose, double-blind placebo-controlled studies are needed in 
healthy individuals with a larger number of test persons in order to consider the expected 
interindividual fluctuations. There is also a need to clarify possible interactions, e.g. with al-
coholic beverages (cf. 3.1.2.1.1.5). 
 
3.1.2.1.1.3 Pharmacokinetics – Warnings for lactation period 
After peroral administration, morphine is relatively quickly absorbed from the gastrointestinal 
tract, mainly from the upper small intestine and, to a lesser degree, from the stomach. The 
low bioavailability (20% - 40%) in the case of peroral morphine administration can be attrib-
uted to presystemic elimination through metabolisation in the intestinal mucosa and liver (in-
testinal and hepatic first-pass-effect) (42, 38, 39, 32). The plasma half-life of morphine is 2 – 
3 hours. Around 30% of morphine is bound to plasma protein. Morphine spreads throughout 
the body with high tissue concentrations in the kidneys, liver, gastrointestinal tract, lungs and 
spleen and low concentrations in the brain and muscles (39, 42). Although the brain is the 
primary site of action of morphine, it has difficulty passing the blood-brain barrier since 80% 
is present in ionised form. In the liver and intestine morphine is mainly metabolised to mor-
phine-3-glucuronide and in lower amounts to morphine-6-glucuronide whereby the latter con-
tributes to its analgesic effect. The half-life of glucoronides is far longer than that of mor-
phine. Morphine and its glucuronides are subject to enterohepatic circulation. Other active 
metabolites are, for instance, the oxidative metabolites, normorphine and codeine. 10% of 
the administered morphine is found in unchanged form in urine. Most of the metabolites are 
excreted via the kidneys (90 %), but also via the liver and gall bladder. The fact that lower 
morphine doses are recommended for older patients has to do with the lower distribution 
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volume and reduced renal function. Morphine can cross the placenta (32, 39, 42). Following 
the administration of therapeutic doses, morphine is detected in breast milk (39, 42).  
 
Lactation 
 
Morphine is excreted in human milk and reaches higher concentrations there than in the ma-
ternal plasma. As clinically relevant concentrations can be achieved in the infant, lactation is 
advised against (42) unless there is a strong therapeutic indication. So far there have been 
no reports of harm to babies following therapeutic applications. Hence, it is not normally 
deemed necessary to stop breastfeeding following the administration of a single dose of 
morphine (41). The American Academy of Paediatrics has stated that the taking of morphine 
is normally reconcilable with lactation. Moreover, it also points out that there are no reports of 
adverse reactions in babies although measurable morphine levels may occur in their blood 
(39). 
 
3.1.2.1.1.4 Tolerance and dependence 
Tolerance development as well as strong physical and psychological dependence occur in 
conjunction with the chronic intake of morphine and rank amongst its most important adverse 
reactions. They can occur in all patients and are not an indication of abuse. Cross-tolerance 
and cross-dependence develop solely between opioids interacting with the same receptor 
(32, 38).  
 
Tolerance 
 
Tolerance can be defined as the reduction in response (e.g. analgesia) to a drug after re-
peated administrations. The degree of achieveable tolerance is high in the case of morphine 
and is indicated as a 10 to 20-fold dose increase. Tolerance concerns all opioid effects be-
sides miosis and obstipation. There is lower tolerance of the respiratory depressive effect 
than, for instance, of analgesia (32). 
 
Psychological and physical dependence 
 
Dependence consists of two components. Psychological dependence is an initially controlla-
ble but later irresistible craving for the drug. It develops from the euphorising properties of 
morphine. Physical dependence is a condition in which the opioids are essential for the nor-
mal functioning of the body. When the opioid is no longer taken, it manifests in the form of 
withdrawal symptoms (32). 
 
The short-term taking of morphine is not linked to any risk of dependence (1). The risk of  
psychological dependence is reduced in the case of the regular administration of morphine 
with even plasma effect levels concerning the analgesic range, as is the case in patients suf-
fering from chronic pain. Physical and psychological dependences are frequent in the case of 
highly fluctuating plasma concentrations as occur in conjunction with abuse (1, 42). 
 
3.1.2.1.1.5 Adverse reactions and resulting warnings 
In the case of adverse morphine reactions, which have already been explained in part under 
3.1.2.1.1.2., a distinction is made between those under normal and high therapeutic doses 
(38, 39, 41, 42).  
 
Adverse reactions at normal doses: 
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Frequently: nausea, retching, obstipation, light-headedness, dizziness, headaches, mood 
swings (euphoria or dysphoria), changes in cognitive and sensory abilities (e.g. blocking of 
thought processes, perceptive disorders, confusion), changes in activation (mostly dampen-
ing), dryness of the mouth, flushed face, perspiration, restlessness, miosis, disruptions in 
bladder emptying, hypersensitivity reactions, pruritus. 
Occasional: bradycardia, tachycardia, cardiac palpitations, hallucinations. 
 
Adverse reactions at high doses: 
Respiratory depression, hypotonia, cramps (particularly in children), muscle rigidity. 
 
Effects on ability to drive and operate machinery: 
A warning is issued that the oral administration of morphine may impair the ability to drive or 
to operate machinery owing to changes in attentiveness and reactive skills (39, 42). This is to 
be expected in particular at the beginning of treatment and when combined with alcohol or 
sedatives (42). Opinions currently differ as to whether steady, long-term treatment with toler-
ance development in pain patients leads to an impairment of their ability to drive. It seems to 
be subject to individual variations (44, 51-56). 
 
Pregnancy 
Development and reproduction toxicity  
Morphine crosses the placenta barrier (cf. 3.1.2.1.1.3.). Adequate data are not available for 
human beings which would permit an assessment of the possible teratogenic risk (42). How-
ever, there have been reports of a possible association with the elevated incidence of her-
nias. Respiratory depression and withdrawal symptoms occur in neonates particularly of de-
pendent mothers. Furthermore, foetal cardiac frequency may be reduced. Other clinical signs 
in neonates are muscular hypertonus, hyperactivity, cramps, shrill crying, tremor, vomiting, 
diarrhoea, sneezing and tachypnoae. Delayed language development may also be a seque-
lae (1).  
 
In published development toxicology studies, morphine was not administered orally but only 
subcutaneously or intraperitoneally (61-66). There were reports of, for instance, CNS mal-
formations (65, 61, 69), retarded growth, reduced litter size, a higher number of stillbirths, 
increased mortality of offspring (62), rib and vertebrae coalescence (69) and cryptorchismus 
(failure of the testes to descend into the scrotum) (64). Furthermore, morphine affected male 
sexual behaviour and female fertility in various animal species (42). The derivation of thresh-
old doses for development and reproduction toxic effects is not possible on the basis of the 
knowledge currently available. 
 
Morphine may only be prescribed according to strict medical criteria during pregnancy in 
cases in which the benefits for the mother outbalance the risks for the child (41, 42). 
 
Delivery 
Morphine can prolong or shorten the length of labour. Neonates whose mothers were given 
opioid analgesics during labour should be monitored for signs of respiratory depression or 
withdrawal symptoms and, if necessary, treated with a specific opioid antagonist (42). 
 
Children 
In the case of children under the age of 1, morphine may only be administered with extreme 
caution as they are more sensitive to the inhibiting effect on respiratory function (42). 
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3.1.2.1.1.6 Experimental findings and resulting warnings 
Genotoxicity/carcinogenicity 
The Federal Institute for Medicinal Products and Medical Devices (BfArM) assesses genotox-
icity based on the findings available to them as follows (42): 
"There are clear positive findings on mutagenicity which indicate that morphine has a clasto-
genic effect and that it exerts such an effect also on germ cells. Hence morphine is to be 
considered as a mutagenic substance; an effect of this kind must also be assumed in human 
beings. -  Morphine should only be taken in conjunction with safe contraception". 
 
According to published investigations the in vivo administration of morphine to mice led to an 
increased incidence of chromosomal aberrations in bone marrow cells (57) and to the induc-
tion of micronuclei in bone marrow cells and lymphocytes (58, 59). Since the number of mor-
phine-induced micronuclei in mice can be reduced through naloxone, an opioid antagonist, 
this genotoxic effect of morphine seems to be at least partially receptor-mediated (59). Since 
attempts failed to induce chromosomal aberrations or micronuclei in vitro, it is assumed that 
there is metabolic activation in vivo. In one in vitro test in human HUT-78 cells, morphine 
increased the mutation frequency and DNA damage (59). Tests on Drosophila, Salmonella 
and yeast cells were negative (59, 60). 
 
No long-term studies in animals are available concerning the tumorigenic potential of mor-
phine. 
 
Reference has already been made in Chapter 3.1.2.1.1.5 to data on development and repro-
duction toxicology from animal experiments. 
 
3.1.2.1.1.7 Clinical pictures for which precautionary measures or warnings are necessary 
Application restrictions (medical supervision or, where appropriate dose reduction) are nec-
essary in conjunction with the oral intake of morphine in the therapeutic range for the follow-
ing diseases (41, 42): 
- Opioid dependence 
- Impaired consciousness 
- Conditions in which a disorder of the respiratory centre and respiratory function is present 
or must be avoided 
- Pulmonary heart 
- Conditions involving elevated cerebral pressure unless ventilation is given 
- Hypotension in the case of hypovolaemia 
- Prostate hyperplasia with formation of residual urine (danger of bladder rupture through 
urine retention) 
- Narrowing of the urinary tract or colics of the urinary tract 
- Biliary tract diseases 
- Obstructive and inflammatory intestinal diseases 
- Phaeochromocytoma 
- Pancreatitis 
- Hypothyroidism 
- Epileptic seizures or increased susceptibility to cramps. 
 
The following warnings are issued in conjunction with specific diseases or disease-related 
situations (42): morphine should be used with caution pre-operatively and post-operatively 
because of the higher risk of ileus or respiratory depression compared with non-operated 
individuals in the post-operative phase. 
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Given the analgesic effect of morphine, severe intraabdominal complications like intestinal 
perforation may be masked. 
 
In the case of existing adrenal cortical insufficiency (e.g. Addison's Disease), the plasma cor-
tisol concentration should be monitored and, where appropriate, replaced with corticoids. 
 
3.1.2.1.1.8 Contraindications 
Hypersensitivity to morphine, ileus and acute abdomen are listed as contraindications for 
morphine treatment (42). 
 
3.1.2.1.1.9 Interactions 
A warning is issued about the following interactions of morphine in medicinal usage (42): 
the parallel administration of morphine and other central depressant drugs like tranquillisers, 
anaesthetics, hypnotics and sedatives, neuroleptics, barbiturates, antidepressants, antihis-
tamines/antiemetics and other opioids or alcohol can exacerbate the side effects of morphine 
at normal doses. This applies in particular to the possibility of respiratory depression, seda-
tion, hypotonia or coma. 
 
Pharmaceuticals with an anticholinergic effect (e.g. psychopharmaceutics, antihistamines, 
antiemetics, drugs to treat Parkinson's Disease) can increase the anticholinergic side effects 
of opioids (e.g. obstipation, dryness of the mouth or miction disorders). 
 
The administration of cimetidine and other pharmaceuticals which strain hepatic metabolism 
can lead to elevated plasma concentrations of morphine (inhibition of degradation). 
 
Morphine can increase the effect of muscle relaxants. 
 
In case of preliminary treatment to patients involving specific antidepressants (MAO inhibi-
tors) (within the last 14 days prior to opioid administration), life-threatening interactions with 
the central nervous system, respiratory and circulatory function have been observed after the 
administration of pethidine. This cannot be ruled out for morphine either. 
 
The parallel administration of rifampicine can weaken the effect of morphine. 
 
3.1.2.1.1.10 Intoxications  
Acute morphine intoxication normally manifests in the three symptoms miosis, respiratory 
depression and unconsciousness (coma). Respiratory depression is the most important risk 
in conjunction with opioid overdose. The direct cause of death is respiratory arrest (32). In 
individuals who do not show any tolerance development, serious toxic symptoms may al-
ready occur after the oral administration of 40 to 60 mg morphine (38). For adults doses from 
200 mg morphine may be acutely lethal (11). Other sources give a range of 300 mg-1500 mg 
for morphine hydrochloride trihydrate (equivalent to 228 mg-1139 mg morphine) for the oral 
lethal doses in the case of non-opiate-dependent adults whereby babies and infants are far 
more sensitive (9). In older literature there are data indicating that it is unlikely that a normal 
pain-free adult would die when given oral doses below 120 mg morphine (38). 
 
In individual cases morphine overdose leads to symptoms ranging from light-headedness 
over stupor to coma. Blood pressure initially remains normal but quickly falls as intoxication 
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advances. A persistent drop in blood pressure can lead to a state of shock. Tachycardia, 
bradycardia and rhabdomyolysis may occur. Body temperature falls. The skeletal muscles 
relax; general cramps may occur particularly in children. As a result of inadequate oxygen 
supply, any skin areas still receiving blood turn blue (cyanosis). Death is normally caused by 
respiratory insufficiency or complications like pulmonary oedema (11,42). 
 
3.1.2.1.2 Codeine 
The phenathrene alkaloid codeine ((5R,6S,9R,13S,14R)-4,5-E poxy-3-methoxy-N-methyl-7-
morphinen-6-ol, MW: 317.4, CAS No.: 76-57-3) is the 3-methylether of morphine. It is nor-
mally used pharmaceutically in the form of its salts, e.g. as codeine phosphate hemihydrate 
(MW: 406.4, CAS No.: 41444-62-6) (39). 
 
3.1.2.1.2.1 Applications 
Codeine is used to treat moderately severe pain, acute diarrhoea but mainly for the sympto-
matic treatment of dry coughs. In the case of the latter the following dose ranges are recom-
mended (43,67): 
 
Table 8: Recommended single and total daily doses for orally administered codeine to treat dry 
coughs (67) 
 
Age Single dose 
codeine 
Maximum daily dose 
codeine 
2 – 6 years 2.5 – 5 mg, 
can be repeated every 6 – 8 hours 
30 mg 
6 – 12 years 5 – 15 mg, can be repeated every 6 – 8 hours 60 mg 
Age 12 up-
wards 
15 – 44 mg, can be repeated every 6 – 8 hours; 
in individual cases up to 100 mg 
200 mg 
 
Other sources indicate for children when codeine is administered orally as an antitussive 
agent 0.25 mg/kg body weight 4 – 6 times daily and as an analgesic 0.5 mg/kg body weight 4 
– 6 times daily (9). For adults the orally administered single dose of codeine as an antitussive 
agent is 10 – 20 mg (maximum daily dose: 120 mg) and as an analgesic 15 – 60 mg (up to 6 
times daily) (9). The lowest single dose indicated for children in the literature is 3 mg codeine 
for children aged 5 (39). The highest single oral dose indicated for children aged 12 upwards 
and adults is 0.1 g codeine (cf. Table 8) (9, 67). 
 
3.1.2.1.2.2 Pharmacodynamics 
Codeine has opiate-agonistic properties. It has an analgesic effect whereby it possesses 
around 1/12 of the pain- alleviating efficacy of morphine. Furthermore, it has an antitussive 
effect (suppresses the cough reflex) by acting on the medulla oblongata in the cough centre. 
This effect is far stronger than in the case of morphine. Furthermore, codeine has slight se-
dating properties. The effects are partly mediated by binding to the supraspinal opiate recep-
tors (µ-receptors) whereby codeine has a considerably low affinity to the opiate receptors. 
The metabolite morphine is responsible for some of the effects (9, 67, 39). 
 
3.1.2.1.2.3 Pharmacokinetics – Warnings for lactation period 
Codeine is readily absorbed from the gastro-intestinal tract whereby, following administration 
of codeine phosphate, the maximum plasma concentration is reached after around one hour 
(32, 39, 67). Bioavailability shows interindividual variations of 40 – 70% (9). Because of the 
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OH group in the 3-position protected by methylation against the conjugating enzymes, co-
deine shows a lower first-pass effect than morphine. The most important biotransformations 
are O and N demethylations in the liver to, amongst others, morphine, norcodeine and nor-
morphine. Codeine and its metabolites are almost fully excreted via the kidneys mainly as 
glucuronides (9, 67). 
 
The codeine elimination half-life is 3 to 5 hours in healthy adults; in the case of renal insuffi-
ciency it may be between 9 and 18 hours. The elimination of codeine is also slower in old 
age (67). 
 
Codeine penetrates the placenta barrier and enters foetal circulation.  
 
Lactation 
Codeine is excreted in breast milk in which it reaches a 2.5 fold higher concentration than in 
plasma. The half-life is 3 hours. After administration of 60 mg codeine to breastfeeding 
mothers, codeine was detected in the plasma of the babies in probably sub-therapeutic con-
centrations (39). When mothers are treated with single therapeutic doses, a risk to the baby 
is unlikely. However, adverse reactions cannot be ruled out in the infant following the admini-
stration of very high doses or repeated treatments with high doses during lactation. If therapy 
of this kind is necessary, mothers should refrain from breastfeeding during treatment (67). 
 
3.1.2.1.2.4 Tolerance and dependence 
Codeine has a primary dependence potential. In the case of longer use and high doses, tol-
erance and physical/psychological dependence develop. The risk of dependence is low com-
pared to morphine. There is cross-tolerance with other opioids (32, 67). 
 
In the case of an existing opiate dependence (also in remission), rapid relapses are to be 
expected. Codeine is used by heroin addicts as a substitute. Alcohol and sedative addicts 
also tend towards codeine abuse and dependence (67). 
 
3.1.2.1.2.5 Adverse reactions and resulting warnings 
The adverse reactions to codeine are similar to those with morphine. All the same, they are 
less developed in therapeutic doses. In the case of chronic administration in normal doses, 
the most frequent side effect is obstipation (32, 39). At high doses excitability and cramps 
particularly in children were frequently observed (9). At higher doses impaired vision, respira-
tory depression and euphoria may also occur (67). 
 
The following are mentioned as frequent side effects: slight headaches, minor sleepiness, 
nausea sometimes linked with vomiting (particularly at the beginning of treatment) and a dry 
mouth. 
 
Allergic reactions to codeine do occur but rarely in a severe form (67). 
 
In order to examine the dose-dependency of CNS-related impaired vision, test persons were 
given 30, 60 or 90 mg codeine phosphate. At the doses of 60 and 90 mg visuomotor co-
ordination worsened and from 90 mg upwards dynamic visual acuity worsened. Sleepiness 
occurred at a dose of 90 mg codeine phosphate (39). 
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Affects on ability to drive and operate machinery 
A warning is issued that even when taken correctly, codeine can influence the capacity of 
reaction which means that the driving of vehicles, the operating of machinery and other dan-
gerous activities are to be avoided at least during the first days of treatment. A decision 
about this is to be taken in each individual case bearing in mind individual reactions and the 
respective dose. The interaction between codeine and alcohol or centrally active medicines 
leads to a major impairment of psychomotor performance. This means that patients are not 
allowed to drive vehicles, operate machinery or engage in any other dangerous activities. In 
a double-blind study the administration of 50 mg codeine phosphate alone or in combination 
with alcohol led to impaired ability in a driving simulation test (70). There is no information 
available on a threshold value for codeine regarding impairment of psychomotor skills. 
 
Pregnancy 
In humans an association was observed between deformities of the respiratory tract and the 
medicinal use of codeine in the first three months of pregnancy. There are also reports of 
other malformations from epidemiological studies involving narcotic analgesics, including 
codeine (67). Attention is drawn to the difficulties in interpreting the available studies on de-
velopment toxicity, e.g. as a consequence of multiple substance exposure (68). For instance, 
studies on the use of codeine to treat pain and a high temperature did not reveal any ele-
vated risk of malformation. By contrast, other studies showed an association between mater-
nal opiate administration (mainly codeine) and cleft lip and pallet in children or highlighted 
postnatal development difficulties (68). 
 
In animal experiments on development toxicity the NOAEL (no observable adverse effect 
level) of codeine was higher than the normal therapeutic doses. For instance in one study in 
which codeine was given with drinking water, 20 mg codeine/kg body weight/day was estab-
lished for hamsters and 75 mg/kg body weight/day for mice as the NOAEL for development 
toxicity (71). For an adult weighing 60 kg the lower NOAEL (20 mg /kg body weight/day) has 
a margin of factor 120 to the lowest antitussive single dose of 10 mg codeine/person (167 
µg/kg body weight) but only a margin of factor 10 to the highest antitussive daily dose of 120 
mg codeine/person (2 mg/kg body weight). 
 
In a rat study an embryotoxic effect was only observed at the highest dose following oral ad-
ministration of 10, 35 or 120 mg codeine/kg body weight from the 6th to the 15th day of gesta-
tion. In the case of oral administration of 5, 12.5 or 30 mg codeine/kg body weight from the 
6th to the 18th day of gestation, no teratogenic effect was observed (72). 
 
Given the data available for humans and the reports of teratogenic potential from animal ex-
periments, codeine may only be prescribed as medicine during pregnancy, particularly during 
the first three months, in line with strict therapeutic indication and careful weighing up of the 
risks and benefits (67). 
 
In the case of imminent birth or imminent abortion, the use of codeine is contraindicated as 
codeine crosses the placenta barrier and can lead to respiratory depression in the neonate 
(67). 
 
In the case of longer-term administration of codeine, an opioid-dependence can develop in 
the foetus. There are reports of withdrawal symptoms in neonates following the repeated 
administration of codeine in the last trimester of pregnancy (67).  
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3.1.2.1.2.6 Experimental findings 
Genotoxicity/carcinogenicity 
Codeine was examined and assessed by the American National Institute of Health (NIH) 
within the National Toxicology Programme (NTP) (68). There were no signs of carcinogenic 
activity of codeine from the two years feeding studies in rats and in mice. 
 
Codeine phosphate did not show any mutagenicity in tests involving four strains of Salmo-
nella typhimurium in the presence or absence of S9. Depending on the dose it did, however, 
lead with and without metabolic activation to an elevated incidence of SCE (Sister Chro-
matide Exchanges) in CHO (Chinese Hamster Ovary) cells. Positive findings were, however, 
only obtained with doses in the cytotoxic range (68). 
 
For further findings of animal experiments, reference to the summary of the NTP report is 
made (68). 
 
Examination of documents relating to medicinal use showed that there were no indications of 
codeine having mutagenic or tumorigenic potential (42). 
 
Findings from animal experiments on the development toxicity of codeine were already ad-
dressed in the previous chapter. 
 
3.1.2.1.2.7 Clinical pictures for which precautionary measures or warnings are necessary 
Application restrictions apply to the oral administration of codeineas medicine. Codeine 
should only be used after serious weighing up of the risk-benefit relationship in the case of:  
- dependence on opioids, 
- impaired consciousness, 
- disorders of the respiratory centre (e.g. conditions involving high cerebral pressure) and 
respiratory function, 
- parallel use of MAO inhibitors, 
- chronic obstructive respiratory disorders(41, 67). 
 
Higher doses of codeine should not be administered in cases of hypotension and parallel 
hypovolaemia. 
 
Treatment of patients after a cholecystectomy should be handled with caution. As a conse-
quence of the contraction of the sphincter oddi, heart attack-like symptoms and an exacerba-
tion of symptoms may occur in the case of an existing pancreatitis. 
 
At the beginning of treatment the individual reaction of the patient to codeine should be moni-
tored in order to quickly identify any relative overdoses. This applies in particular to older 
patients with restricted renal function and respiratory function disorders (risk of a pulmonary 
oedema). 
 
3.1.2.1.2.8 Contraindications 
The following contraindications apply to orally administered codeine (67): 
 
- over-sensitivity to codeine, 
- respiratory insufficiency, 
- respiratory depression, 
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- pneumonia, 
- acute asthma attack, 
- coma, 
- children under the age of 2, 
- imminent birth, 
- imminent abortion. 
 
3.1.2.1.2.9 Interactions 
A warning is issued about the following interactions of codeine following oral administration in 
medicinal usage (67): 
 
The sedating or respiratory depressive effect can be exacerbated by the parallel taking of 
codeine and other central depressants like sedatives, hypnotics or psychotropics (phenothi-
azines like chlorpromazine, thioridazine, perphenazine) as well as antihistamines (like pro-
methazine, meclozine) and antihypertensives. 
 
Alcohol should be avoided when taking codeine as psychomotor abilities may be considera-
bly diminished (supraadditive effect of individual components). 
 
In conjunction with trycyclic antidepressants (imipramine, amitriptyline) and opipramole, co-
deine-related respiratory depression may be exacerbated. 
 
The parallel taking of MAO inhibitors like tranylcypromine can lead an enhancement of ef-
fects on the central nervous system and other side effects on a non-foreseeable scale. Co-
deine may not, therefore, be administered until two weeks after the end of treatment with 
MAO inhibitors. 
 
The effect of analgetics is enhanced. The parallel administration of partial opioid ago-
nists/antagonists like buprenorphine, pentacozine may weaken the effect of codeine. 
 
Cimetidine and other medicinal drugs, which influence hepatic metabolism, may increase the 
effect of codeine. During morphine treatment an inhibition of morphine degradation with con-
secutively elevated plasma concentrations was observed. Interaction of this kind cannot be 
ruled out for codeine. 
 
3.1.2.1.2.10 Intoxications 
The symptoms of codeine overdose are similar to those of acute morphine intoxication (cf. 
3.1.2.1.1.10). Here, too, extreme respiratory depression is characteristic. It ranks amongst 
the most frequent severe complications along with pulmonary oedemas. Symptoms ranging 
from extreme sleepiness over stupor to coma may occur. At the same time, this may be cou-
pled with miosis, vomiting, headaches, urine and faeces retention, cyanosis, hypoxia, cold 
skin, skeletal muscle tone loss and areflexia and, in some cases, with bradycardia, syncopes 
and a drop in blood pressure. Particularly in children sometimes only cramps occur (9, 67). 
 
In case of codeine intoxication the risk is deemed to be particularly high for children. This 
was shown by an evaluation of clinical data on acute codeine intoxications in 430 children 
(73). Out of 234 children who had been given more than 5 mg codeine/kg bodyweight, 8 suf-
fered from respiratory arrest and required intensive care. 2 of them died. In the other cases 
one or more of the following symptoms were observed as a consequence of intoxication: 
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sleepiness, ataxia, miosis, vomiting, rashes, swelling, smarting of the skin but no life-
threatening effects. 
 
In clinical terms toxic symptoms are to be expected in adults at a total dose of 0.5 – 1 g co-
deine and in children from doses of 2 mg codeine/kg body weight upwards. 
 
3.1.2.1.3 Papaverine 
Papaverine (6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline, MW: 339.4, CAS No.: 58-
74-2) is a benzylisoquinoline alkaloid (10, 39); papaverine hydrochloride, MW: 375.8 (CAS 
No.: 61-25-6).  
 
The myotropic spasmolytic papaverine has a direct relaxing effect on smooth muscle (1, 9, 
32). The effect is attributed to an inhibition of phosphodiesterase (32, 39). It does not bind to 
opioid receptors. Today, papaverine is only rarely used to treat spasms of the gastro-
intestinal tract, bile ducts, urinary tracts and bronchi (9, 32). The oral dose is 0.1 g adminis-
tered several times daily. The maximum daily dose is indicated as 600 mg papaverine hydro-
chloride (equivalent to 542 mg papaverine) (39). 
 
After oral administration it is readily absorbed. Bioavailability is about 55 %. Nevertheless, 
efficacy is not reliable in the case of oral administration. Plasma protein binding is about 
90%. Papaverine is mainly metabolised in the liver and excreted renally in the form of glu-
curonidated phenolic metabolites. The half-life is indicated as 0.5 to 2 hours. 
 
The side effects which occur after oral administration are dizziness, headache, tiredness, 
gastro-intestinal disturbance, flush, skin rash, tachycardia, sweating and hypotonia. In con-
junction with long-term administration eosinophilia, liver enzyme changes (reversible) and 
icterus may occur (9, 39). 
 
There are application restrictions for patients with glaucoma and prostate hypertrophy. 
 
Increased intracranial pressure and atrioventricular block are contraindications (9). 
 
There are strict therapeutic indications for pregnancy and lactation period (1). 
 
Reduced efficacy of levodopa is stated as an interaction (39). 
 
3.1.2.1.4 Noscapine 
Noscapine ((3S)-6,7-Dimethoxy-3-[(5R)-5, 6, 7, 8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo 
[4, 5,-g]isoquinoline-5-yl]phthalide (formerly narcotine, MW: 413.4, CAS No.: 128-62-1) is 
also an alkaloid of the benzylisoquinoline type (10, 39). 
 
Noscapine is an opium alkaloid which is chemically related to papaverine. It is a centrally 
acting cough supppressant. It does not react with opioid receptors and is not, therefore, con-
sidered to be an opioid. It has neither an analgesic, respiratory depressive or obstipating 
effect (32). Its antitussive effect is said to be weaker than that of codeine (1). It has no de-
pendence potential (32). It has a weaker spasmolytic effect than papaverine. Noscapine 
demonstrates weak bronchiodilatory properties and stimulates respiration (1, 9). It is used to 
treat dry cough. For adults the dose is 25-50 mg 3 times daily, for children aged between 3 
and 12, 12-25 mg 3 times daily and for children aged between 6 months and 3 years 6-12 
mg 2-3 times daily    (1, 9, 39). 
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After oral administration noscapine is readily and quickly absorbed. Because of a first-pass 
effect bioavailability varies considerably intraindividually and interindividually. It is about 30%. 
The half-life is 1-4.5 hours; the antitussive effect lasts for 4-6 hours. Noscapine is excreted 
renally -  to a low degree unchanged and, for the most part, in metabolised form (1, 9). Slight 
sleepiness, light-headedness, dizziness, headaches, nausea and erythema are indicated as 
adverse reactions. Reactivity may be impaired (9, 32). 
 
Noscapine may lead to the release of histamine. At high doses it triggers bronchoconstriction 
and temporary hypotonia (38). 
 
Hypersensitivity to noscapine is a contraindication (1, 9). 
 
There are no reports of clinically relevant interactions (9). 
 
Pregnancy and lactation 
Noscapine is a poison of mitotic spindle formation. In contrast to other agents of this kind its 
interaction with tubuline dimers is reversible and depends on its concentration. Cell division 
in the metaphase is only stopped at noscapine concentrations equivalent to roughly 100 
times the therapeutic daily dose for adults (150 mg). Given the elimination half-life of maxi-
mum 4.5 hours, the influencing of cell division at therapeutic doses is considered to be 
unlikely. Application during the first trimester of pregnancy should, however, only be under-
taken in cases of strict therapeutic indications (1, 9, 39). 
 
At a maternal daily dose of 100 to 150 mg noscapine administered to 8 women, noscapine 
was only found in amounts of 11-83 ng/ml in milk (39). At a maternal daily dose of 150 mg an 
uptake of 300 ng noscapine/kg body weight was assumed from milk. A risk to babies from 
this dose was considered to be unlikely. Hence, as also stated by the American Academy of 
Paediatrics (39), there are no objections to the therapeutic use of noscapine during lactation 
period (9). 
 
Intoxication 
During the treatment of tumours orally administered doses in the range of 1 to 3 g were well 
tolerated by 80% of patients. The other 20% suffered from minor sedation, nausea and eme-
sis. Signs of intoxication are only to be expected from a dose of 4 to 6 g/day upwards (1). 
 
3.1.2.1.5 Thebaine 
Thebaine (6,7,8,14–Tetradehydro-4,5-epoxy-3,6-dimethoxy-17-methyl-morphinan, MW: 
311.4, CAS No.: 115-37-7) contains the basic structure of morphinan like morphine and co-
deine. Therefore, it is classed as a phenanthrene alkaloid. 
 
Since thebaine is not used pharmaceutically but only as a starting substance for pharmaceu-
tic synthesis, no information is available about its effects in humans. In animal experiments a 
LD 50 of 114 mg/kg body weight was determined in rats and a LD 50 of 54 mg/kg body 
weight in mice following oral administration (76). No other animal experiments are available 
involving oral administration. From the experiments described and the scientific literature, it 
can be derived that it mainly has a stimulating effect on the CNS. In all animal species inves-
tigated it led to cramps (32, 75, 77). In rabbits thebaine antagonised respiratory depression 
caused by morphine (Table 9,  3.1.2.1.2) (74, 77). In a mixture with noscapine it provoked a 
strong respiratory stimulation. In a behaviour test in rhesus monkeys, at increasing doses, it 
manifested first tremor then cramp and light-headedness. Furthermore it was demonstrated 
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that, when applied at high doses over a longer period to rhesus monkeys, thebaine led to 
psychological and physical dependence (77).  
 
3.1.2.1.6 Opium 
Opium is the air-dried latex obtained by incisions from the unripe capsules of Papaver som-
niferum L. (cf. 3.1.1.1). Here, only brief attention will be paid to the effects of opium from the 
angle of alkaloid interactions. Assuming that the high alkaloid content in poppy seeds is 
caused by contamination with the latex or that opium alkaloids adhering to poppy seeds have 
a distribution pattern similar to that found in opium, then statements in the scientific literature 
about the combined effects of the alkaloids in opium may be relevant for alkaloid-
contaminated poppy seeds, too. The toxicity of opium, including possible lethal depression of 
the respiratory centre, is based primarily on the toxic effect of the main alkaloid morphine. 
The overall effect of opium is a result of the synergistic and antagonistic effects of the indi-
vidual opium alkaloids (1, 2) which are presented in simplified form in Table 9. 
 
Table 9: Central effects of opium alkaloids (presented in abbreviated form according to 1, 2) 
 
 Morphine Codeine Thebaine Papaverine 
Analgesic effect 
 
+++ ++ - - 
Hypnotic effect 
 
+++ + - - 
Effect on the respiratory 
centre 
Paralysing - Exciting - 
 
As shown by Table 9, it can be assumed that codeine can increase the analgesic and hyp-
notic effects of morphine. Morphine is said to have a higher analgesic effect than its mor-
phine level would correspond to (1).  
 
Opium has a paralysing effect on the central nervous system, particularly on the respiratory 
centre. The paralysing effect of morphine is said to be reduced in opium because of the an-
tagonistic effect of thebaine (1, 2). Noscapine also has a minor stimulatory effect on respira-
tion. The peripheral effect of opium is mainly increasing the tonus of smooth muscles, in par-
ticular the sphincter muscles. The stimulating effect of morphine on smooth muscle is set 
against the spasmolytic effect of papaverine. According to older data, the antidiarrhoeal ef-
fect of opium is due to the triggering of atonic obstipation (in contrast to the spastic effect of 
morphine). 
 
3.1.2.2 Poppy seeds 
3.1.2.2.1 Adverse reactions and intoxications after consumption of poppy seeds 
Already in older toxicological standard works it is reported that the consumption of large 
amounts of commercially available poppy seeds, e.g. in the form of deserts with approxi-
mately 10 – 20% poppy seeds or poppy seed cakes, can lead to light-headedness and en-
teroparesis in sensitive individuals (28). 
 
The symptoms described in a consumer complaint made to the official food control also 
agree with the range of toxicological actions of morphine. This complaint was passed on to 
us by. After eating a dish, which had been sprinkled with a mixture of ground poppy seed and 
sugar, a consumer observed an "uneasy feeling" in her head, had to vomit and felt like she 
had a hangover the next day. The person concerned had ingested approximately 75 g blue 
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poppy seeds, containing 210 µg morphine/g and 39 µg codeine/g. This corresponds to intake 
doses of 16 mg morphine and 3 mg codeine. The poppy seeds were deemed to have a 
health- injuring potential (within the intendment of Article 14 para 2a and para 4 of Regulation 
(EC) 178/2002).injuri                                                                                                                                          
 
Further information from forensic studies in test persons is available concerning the ques-
tions about the dose range at which morphine ingestion from poppy seeds can lead to ad-
verse reactions. 
 
Moeller et al. (24) gave various poppy seed-containing products (rolls, cake) to five test per-
sons (three men and two women, aged: 22 – 43, body weight 55 - 102 kg). The morphine 
content of the poppy seeds was 50 µg/g; unfortunately, the amounts of biscuits or poppy 
seeds consumed were not documented. Directly after consumption the test persons were 
examined by a trained policeman using a checklist for routine tests for drug consumption in 
car drivers. This test proved negative. A general practitioner also examined the test persons. 
Only one of the test persons (55 kg), who had eaten the largest amount of poppy seed cake, 
reported a slight drug effect involving light-headedness with reduced reaction time of the pu-
pils. No free morphine or codeine was found in the serum of any of the five test persons. 
However, after hydrolysis of the morphine conjugates morphine could be detected using 
GH/MS (highest value: 24 ng/ml). Morphine and codeine could be detected in the urine of all 
test participants following hydrolysis. 
 
In the comprehensive investigations by Westphal et al. (29, 30) 20 test persons (8 female, 12 
male) aged between 19 and 45 consumed between 25 g and 250 g poppy seed in the form 
of poppy seed rice pudding and/or poppy seed cake within 90 minutes. They had been in-
structed to eat as much as they could. The two poppy seed batches used showed morphine 
levels of 72.4 µg/g and 114.3 µg/g. Only half of the test persons had breakfasted that morn-
ing prior to the test. Serum collected 1, 2, 4, 8 and 24 hours after consumption was found to 
contain morphine and codeine individually and together. When the last blood sample was 
taken the test persons described their condition since ingesting poppy seeds. 7 test persons 
did not describe any effects. By contrast, the 13 others indicated one or more of the following 
symptoms: tiredness, lack of drive, difficulty concentrating, headache, dizziness, ongoing dry 
mouth, minor to severe nausea down to vomiting, heavy tongue, impaired field of vision. 
Since the publications (29, 30) did not permit any allocation of the symptoms to the individual 
test persons and no relevant dose assocations could, therefore, be identified, BfR got back to 
the authors who were so kind to provide more detailed information (33). In the case of the 
symptoms listed, aside from "constricted pupils, heavy sweating and dry mouth" all other 
symptoms had been observed by the test persons themselves. There was no medical obser-
vation as the experiment had not been designed to examine morphine symptoms. The co-
deine intake is not covered here. Reference is made to the original work. 
 
The lowest morphine dose at which adverse reactions, i.e. listlessness, shortage of power 
and sleepiness were reported, was 2.9 mg in absolute terms and 40.2 µg/kg body weight. It 
can be assigned to test person T who only wanted to eat 25 g poppy seeds and for whom the 
detection of free morphine in serum was positive but not quantifiable since it was between 
the detection limit of 0.74 ng/ml and the determination limit of 2.82 ng/ml. The authors voiced 
doubts about whether the symptoms could be attributed to the action of poppy seeds. At the 
next higher morphine intake level of 8.3 mg in absolute terms, equivalent to 109.6 µg/kg body 
weight, the test person A did not observe any adverse reactions. Out of the 8 test persons 
who ingested 11.4 mg morphine in absolute terms, 2 did not observe any effects (test per-
sons J and O). By contrast, 6 test persons described adverse reactions:  
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- Test person F (134.5 µg morphine/kg body weight) 10 - 12 hours after ingestion suffered 
from nausea without vomiting and reduced saliva, 
- Test person H (190.5 µg morphine/kg body weight) suffered from slight nausea during 
the last bite, 
- Test person K (142.9 µg morphine/kg body weight) suffered from tiredness and head-
aches (forehead and left half of head) about 7 hours after intake, dizziness whilst blood 
was being taken after 8 hours, 
- Test person M (152.4 µg morphine/kg body weight) suffered from nausea, headache, 
tiredness, hiccups, 
- Test person R (152.4 µg morphine/kg body weight) suffered from a sensation of reple-
tion, nausea, problems concentrating, tiredness, 
- Test person S (170.6 µg morphine/kg body weight) suffered from slight nausea. 
 
Although the sensation of repletion, nausea and tiredness which occurred shortly after eating 
cannot be interpreted as specific effects of morphine since they could be triggered solely by 
consuming large amounts of fat-containing foods, the symptoms of test persons F and K do 
seem to be clearly linked to their morphine intake. At the next higher concentration range the 
three test persons D, B and G, whose morphine intakes were 13.0 (178.5), 14.5 (195.7), 14.3 
(190.5) in absolute mg (relative in µg/kg body weight), did not observe any effects. Test per-
son C with an absolute morphine intake of 14.5 mg (equivalent to 258.6 µg/kg body weight) 
noticed slight light-headedness, increasing nausea and vomiting and hiccups 8 hours after 
ingestion. In the dose range of absolute morphine intake of 17.1 – 18.1 mg, one test person 
(E, 274.2 µg/kg body weight) did not notice any effects whereas a second test person (I, 
263.8 µg/kg body weight) observed headaches in the forehead area, slight nausea, tired-
ness, circulatory weakness 7 hours after intake and a third (P, 281.1 µg/kg body weight) ab-
dominal pain and nausea. At the highest morphine intake levels in the absolute range 20.0 – 
22.9 mg, all three test person manifested morphine-related effects: test person L (266.7 µg 
morphine/kg body weight) described slight nausea during the last bite, ongoing mouth dry-
ness up to 10 hours after intake and slight light-headedness 2.5 hours after intake. Test per-
son N (317.5 µg morphine/kg body weight) reported increasing tiredness up to 9 hours after 
intake, slight impaired field of vision and a heavy tongue. In test person Q the highest free 
morphine value in blood of 17.3 ng/ml was measured at a relative morphine intake of 228.6 
µg morphine/kg body weight 1 hour after eating. 
 
Directly after ingestion he manifested constricted pupils and heavy sweating in addition to 
tiredness and lack of drive as well as severe nausea which developed after 6 hours. Concen-
trations of free morphine in the serum of 10 ng/ml upwards (cf. 3.1.2.2.3 for recommendation 
of 10 ng/ml as the "cut-off value" regarding § 24 a StVG) with a 1-4 hour duration, where a 
calming effect on the organism is generally to be expected (30), were only observed in test 
persons who had ingested more than 14 mg morphine. However, the authors noticed that 
there was no direct proportionality between the ingested morphine amount (even if it were 
placed in relationship to body weight) and the morphine concentration in the serum. Even 
after intakes of more than 14 mg morphine, serum concentrations of free morphine resulted 
which were well below 10 ng/ml. Only in 2 out of 7 test persons, who had not observed any 
effects, were serum values of more than 10 ng/ml temporarily measured (B, G). The influ-
ence of abrosia prior to poppy seed consumption on the serum values or action was not ob-
served. The experiment shows the major variation range of individual reactions to morphine 
intakes despite which a dose-dependent increase in the severity of the effects can be identi-
fied (e.g. from tiredness to light-headedness, from nausea to vomiting). Furthermore, the 
proportion of test persons undergoing adverse reactions increases at higher intake levels. 
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Bjerver et al. (31) describe an experiment in which 7 test persons consumed one or two 
pieces of a poppy seed cake, which contained 5 mg morphine per portion. After intake of 5 - 
10 mg morphine, obstipation was the only morphine effect observed. 
 
In another study 12 test persons (7 female/5 male, age: 23-58 years) ate 1-4 pieces of poppy 
seed cake within 30 minutes. The morphine content of the baking poppy seed was 206 µg/g 
in batch I and 0.6 µg/g in batch II. Each test person ingested between 9 - 55g poppy seeds. 
The blood concentration of free morphine was 8.5 ng/ml after 4 hours in one person and 13.5 
ng/ml after 4.5 hours in another. The only adverse reaction which occurred in all female test 
persons was a major sensation of repletion, in some cases nausea. The authors believe it is 
questionable whether these effects can be attributed to the content of alkaloids in the poppy 
seeds or other ingredients. Other side effects like sleepiness, drop in blood pressure or 
tachycardia were not observed by the authors (22). 
 
In other publications there were reports of a feeling of and sensation of repletion, lethargy (2) 
or obstipation (5) as adverse reactions after consuming poppy seed-containing pastry without 
morphine intake being quantified. 
 
Hayes et al. (23) carried out blood tests in four test persons after consumption of 25 g poppy 
seeds with 294 µg morphine/g and 14 µg codeine/g, equivalent to intake of 7.5 mg morphine 
and 0.4 mg codeine. After hydrolysis they showed 82 - 131 ng total morphine/ml serum (2 
hours after consumption). However, they observed that none of the symptoms caused by 
morphine, like analytic or euphoric effects, were observed. 
 
Finally, attention is drawn to one intoxication incident as a consequence of which BfR warned 
against using baking poppy seeds as a sedative for babies (44). A 6-week old baby suffered 
from severe health impairment including respiratory depression and had to be taken to inten-
sive care after its mother had given it 75 ml of a milk preparation obtained after straining a 
mixture of 200 g poppy seeds and 500 ml milk. In line with the investigations the morphine 
level in the serum of the baby on the following day was 4.3 ng/ml. 0.1 % morphine and 0.003 
% codeine had been detected in the poppy seeds used (cf. 3.1.1.3.1). 
 
By way of summary, it can be said that for the purposes of this risk assessment primarily the 
investigations by Westphal et al. (29, 30, 33) are relevant. This study shows that the con-
sumption of poppy seeds leading to morphine intakes of 11.4 mg or 134.5 µg/kg body weight  
respectively, or above must be assumed to be linked to the occurrence of adverse reactions 
typical for morphine. These findings are consistent with the data provided by official food 
control (light-headedness after intake of 16 mg morphine). Statements on possible adverse 
reactions at lower doses or about threshold doses, below which health impairment can be 
ruled out, cannot, however, be derived from the study by Westphal et al. as only 2 test per-
sons in total were examined in the lower dose ranges. One report of adverse reactions, like 
e.g. sleepiness at an intake of 2.9 mg morphine (equivalent to 40.2 µg morphine/kg body 
weight) is questionable. For morphine intakes of 5 - 10 mg from poppy seeds, another report 
mentions obstipation as a further adverse reaction (31).  
 
The above experiments show that morphine intakes from the matrix of poppy seeds may, 
under the given circumstances, be on the scale of therapeutic morphine doses. They may 
also lead to the spectrum of adverse reactions familiar from medicinal applications. 
 
It is pointed out that the findings of the available forensic studies are only reliable to a very 
limited degree when it comes to risk assessment because of the test design which is oriented 
towards a different question (e.g. no double-blinding, no recording of sensitive psychomotor 
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parameters, low number of test persons per dose group, no medical diagnosis). Hence, there 
is a need for investigations to fill in the identified gaps in knowledge. 
 
3.1.2.2.2 Poppy seed abuse 
On the Internet there are instructions about how to use citric acid to extract opium alkaloids 
from the blue seeds available commercially in Germany for the purposes of abuse. After in-
gesting an extract obtained from 640 g or 350 g poppy seeds by citric acid, signs of tired-
ness, inactivity and warmth are said to have occurred (33). From another source there are 
reports of euphoria, relaxation, inactivity, obstipation and abdominal pain following ingestion 
of an extract prepared with citric acid from 250 g blue poppy seeds. There is a risk that opi-
ate dependence could be triggered through this abuse (cf. 3.1.2.1.1.4). 
 
3.1.2.2.3 Forensic aspects of poppy seed consumption 
The detection of free morphine in serum is interpreted from the forensic angle as an indica-
tion of exposure to specific pharmaceuticals or drugs, i.e. morphine itself or heroin and co-
deine, which can be metabolised into morphine (32). According to more recent findings (29) 
the detection of morphine in serum may also be linked to the consumption of poppy seeds 
containing higher levels of morphine (cf. 3.1.2.2.1). 
 
According to § 24 a Street Traffic Law (StVG) anyone who drives a motor vehicle under the 
influence of, e.g. morphine or heroin acts contrary to orders. An "influence" is assumed when 
morphine is detected in the serum. Only when morphine can be traced to the proper taking of 
a pharmaceutical prescribed for a concrete medical condition, has no regulatory offence 
been committed. The “Grenzwertkommission” which advises the Federal Ministry of Trans-
port, Building and Urban Affairs currently recommends a serum concentration of 10 ng/ml as 
the cut-off value for free morphine below which no prosecution should be pursued. The ex-
ceeding of this value following the consumption of poppy seed-containing foods (cf. 
3.1.2.2.1) creates a problematic assessment situation (29). 
 
3.1.3 Exposure to poppy seeds 
 
Poppy seeds are used directly or after kitchen processing e.g. with mills, through swelling, 
heating, cooking and/or baking in foods. No data are available on possible changes in con-
tents or the bioavailability of the opium alkaloids by these processes. Hence, attention cannot 
focus here on such effects. 
 
The poppy seed coating of rolls, bagels, muffins or other bakery products normally weighs 
between 1 and 4 g/piece (18, 20, 22). For cake preparation ground poppy seeds are mostly 
boiled in milk. This mixture is then baked with other ingredients without straining the milk. 
The poppy seed proportion in conventional recipes is between 10 - 30%, whereby 1 piece of 
cake from a bakery weighs between 150 g and 200 g. 
 
Furthermore, other desserts like “Mohnpielen” contain up to 10 - 20% ground and cooked 
poppy seeds. 
 
Finally poppy seeds (unprocessed) are sprinkled with sugar on traditional dishes like yeast 
dumplings. For the purposes of estimating the level of exposure, reference is made to the 
complaint addressed under 3.1.2.2.1 whereby a dish was sprinkled with 75 g blue poppy 
seeds as part of a mixture with sugar and then eaten. 
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Since poppy seeds contain a high level of fat (cf. 3.1.1.3), their intake is self-limiting by the 
high satiation value. What is of primary importance for risk assessments and maximum level 
derivations are the maximum intakes to be expected within the limits of normal consumption 
in the worst case. Orientation values can be taken from the test by Westphal et al. (33, 34) in 
which the test persons were instructed to eat as many poppy seeds as possible in the form of 
poppy seed rice pudding or homemade poppy seed cakes. Out of the 20 test persons one 
ate 25 g, eight 100 g, two 115 - 125 g, two 150 g, two 175/180 g, four 200 g and one 250 g 
poppy seeds. This test involved specially manufactured high content poppy seed prepara-
tions especially made for this purpose which were consumed under experimental conditions. 
For the purposes of this assessment, it seems realistic to take lower intake levels. In the risk 
assessment the worst case assumed is that an adult weighing 60 kg eats 150 g poppy seeds 
once a day during a meal. This corresponds for a cake with a 25% content of poppy seeds to 
three slices of 200 g or four slices of 150 g. The intake of 50 g poppy seeds once a day dur-
ing a meal is considered to be moderate normal consumption. Intakes of > 50 g up to 100 g 
during one meal per day are regarded as high consumption. For children the example is 
taken of a 5-year-old girl weighing 14.6 kg (5th percentile) (50). Here the worst case assumed 
is the consumption of 75 g poppy seeds, corresponding to the consumption of one and a half 
200 g pieces of cake during one meal a day. Moderate normal consumption is considered to 
be the intake of 25 g poppy seeds and high consumption the intake of 50 g poppy seeds dur-
ing one meal a day. 
 
3.1.4 Assessment and discussion 
 
3.1.4.1 Analytical data on opium alkaloids in poppy seeds – orientational health assessment 
 
The analytical data from various sources provide an overview of the contents of morphine 
and codeine detected in poppy seeds and also, in individual cases, for papaverine, noscap-
ine and thebaine. Data on the identity (batch numbers, question of multiple sample collection 
from the same batch) and origin (e.g. geographical, botanical) of the samples are sparse. 
Because of the non-standardised analytical methods, comparison of the data from the vari-
ous reports is only possible to a limited degree. Data are only available from a few regions in 
Germany.  
 
For the purposes of this risk assessment it is assumed that, within normal consumption, an 
adult eats in the worst case 150 g poppy seeds (three 200 g pieces of cake with 25% poppy 
seed content) during one meal a day (cf. 3.1.3). If doses of the individual opium alkaloids are 
ingested in these portions which are within the range of therapeutic doses, then there is a 
health-injuring potential. On reaching the lowest known therapeutic dose, the occurrence of 
the described pharmacological effects must be considered in sensitive individuals (cf. 
3.1.2.1). 
 
3.1.4.1.1 Morphine 
In the case of morphine, portions of up to 150 g poppy seeds in highly contaminated samples 
(content of up to 330 µg morphine/g, Table 3) would lead to intakes of up to 49.5 mg mor-
phine. As this amount already exceeds the recommended highest oral single dose of 45.6 
mg (Table 7), serious central nervous and peripheral effects are to be expected which in-
clude impaired consciousness, respiratory depression and cardiovascular effects. This is all 
the more so the case as it must be assumed that this mainly concerns the first-time intake of 
this amount of morphine by opioid-naive, healthy individuals. By contrast, in the case of 
chronic pain therapy higher doses are normally only administered after longer treatment in 
the course of which tolerance has already developed. It can be assumed that frequent con-
  Page 32 of 46 
 Federal Institute for Risk Assessment 
sumption of morphine levels of this kind leads to the development of dependence. It is obvi-
ous that highly contaminated poppy seed batches of this kind are dangerous and not mar-
ketable. In Chapters 3.1.4.2 / 3.1.4.3 intake amounts/guidance values are established for 
morphine in poppy seeds. This aims at giving food control authorities decision support con-
cerning the lower morphine concentrations in poppy seeds, upwards of which consumption 
must be deemed to be problematic also from the precautionary health angle. 
 
3.1.4.1.2 Codeine 
In the case of codeine, consumption of up to 150 g of the most highly contaminated poppy 
seed sample from Germany, which had already been focussed because of the high morphine 
values and which had a codeine content of 39 µg/g, would result in an intake of up to 5.85 
mg codeine. In the worst case codeine intake would, therefore, in the case of adults be 1.7 
times lower than the lowest indicated therapeutic single dose of 10 mg (cf. 3.1.2.1.2.1). For a 
5-year-old child with a worst-case consumption of 75 g poppy seeds (cf. 3.1.3), the calcu-
lated intake for this sample would be 2.93 mg, which practically reaches the lowest single 
dose of 3 mg indicated for children of this age. The analogous calculation is even less fa-
vourable for the most highly contaminated poppy seeds from the international retail food 
trade, in which 57.1 µg codeine/g were detected. 
 
High codeine levels only occurred in conjunction with high morphine contents (Tables 2-4). 
By contrast, poppy seed samples with morphine concentrations on the scale of the guidance 
value (cf. 3.1.4.3) mostly have codeine contents below the detection limit and in no case over 
2 µg/g (Table 3: out of the 13 samples with morphine levels ≤ 10 µg/g 12 samples had co-
deine values below the detection limit and only one had a codeine level of 1.8 µg/g. Table 2: 
out of 7 samples with morphine levels ≤ 10 µg/g, the codeine contents of 4 samples were 
below 0.3 µg/g and of 3 samples below 1.08 µg/g). Hence, the establishment of a guidance 
value for codeine, to the extent that the proposed guidance value for morphine is used, is not 
considered to be absolutely necessary under aspects of health. Nevertheless, it is deemed 
wise in order to cater for the possibility that varieties of Papaver somniferum could, for in-
stance, occur during the cultivation of low morphine types of poppy whose seeds have a dif-
ferent alkaloid pattern from the ones examined here. Since, furthermore, it can be assumed 
that codeine enhances toxicologically relevant morphine effects (e.g. central depressant), 
that it is difficult to estimate its further role in possible synergistic effects of opium alkaloids 
and that fundamental aspects of upholding purity and quality criteria have to be considered, 
the codeine contamination of poppy seeds should be kept as low as possible. Given the ex-
isting situation, no derivation of a guidance value is undertaken from the health angle. It is 
recommended to find out, which is the lowest level of codeine in poppy seeds that can be 
technologically met. The guidance value should not be higher than the range of maximum 1 - 
2 µg codeine/g which can currently be derived from Tables 2 and 3.  This leads, in a worst 
case consumption scenario of 75 g poppy seeds by a 5-year-old child, to a margin of factor 
20 and 40 and in the case of high consumption of 50 g poppy seeds to a marginal factor 30 
and 60 to the lowest known therapeutic single dose of 3 mg codeine. 
 
3.1.4.1.3 Papaverine 
 
The values measured in 11 samples from the German retail food trade were below 0.06 µg 
papaverine/g (Table 2),  whereas levels of up to 67 µg papaverine/g (Table 4) have been 
published for the international retail food trade. Thus, in the worst case maximum exposures 
of up to 9 µg and 10 mg per person can result from the consumption of 150 g poppy seeds 
by an adult. The margin to the indicated therapeutic single dose of 100 mg is more than fac-
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tor 10,000 for exposure to samples from the German food retail trade whereas for samples 
with papaverine levels of up to 67 µg/g there is only a margin of factor 10. The extreme varia-
tions in papaverine levels indicate that it is advisable, for the purposes of quality assurance, 
to define a maximum value which can be complied with through good manufacturing practice 
as the guidance value in terms of a purity requirement. It should be below 0.1 and 1 µg/g 
according to the current data available. 
 
3.1.4.1.4 Noscapine 
1.57 µg noscapine/g was the highest content found during the analysising of 11 poppy seed 
samples from the German market (Table 2). The highest value published for the international 
food trade was 230 µg noscapine/g (Table 4). In the worst case, consumption of 150 g poppy 
seeds by an adult would result in intakes of 236 µg and 34.5 mg noscapine. Whereas in the 
case of the first intake mentioned, which refers to samples from the German market, there is 
a margin of factor 106 to the lowest indicated single dose of 25 mg noscapine in adults, the 
intake of 34.5 mg noscapine is already within the range indicated for a single dose of 25 to 
50 mg for the use of noscapine as an antitussive agent. In the case of the poppy seed sam-
ple with 230 µg noscapine, pharmacological effects must already be considered including the 
adverse reactions mentioned under 3.1.2.1.4 (e.g. sleepiness, light-headedness, impairment 
of reactivity, headaches, nausea). This means that this sample has health-injuring potential. 
Although no more details on the origins of the said batch and on the correctness of the 
measurement value are available, the data are nevertheless taken as an indication that 
poppy seeds may contain levels of noscapine which cannot be tolerated from the health an-
gle. Particularly with a view to adverse noscapine reactions that could impair the ability to 
drive or operate machinery, the establishment of a provisional guidance value is recom-
mended below the noscapine level of 2 µg noscapine/g that is considered to be compliable. It 
should reflect technological possibilities. 
 
3.1.4.1.5 Thebaine 
No analytical data are available for thebaine concerning poppy seeds available in the Ger-
man retail food trade. The highest thebaine concentration recorded in Tables 1-6 was 41 
µg/g (4). The few available measurements cannot be considered representative. Since only 
LD 50 values from animal experiments are available as oral effective doses, a risk assess-
ment is scarcely sound. There is a margin of factor 540 between the lowest oral LD 50 of 54 
mg/kg body weight in mice and the maximum intake of thebaine (0.1 mg/kg body weight) by 
an adult weighing 60 kg in the worst case of 150 g poppy seeds. Given the inadequate ana-
lytical and toxicological data available, no statements can be made about the need for guid-
ance values for thebaine from the health angle. Given its obvious potential to produce de-
pendence in rhesus monkeys, it is, however, advisable to define guidance values as purity 
criteria. Here the lowest technologically compliable value should be taken as the basis. As for 
thebaine a maximum level of 20 µg/g is established in Hungary (3.1.1.2), we can assume 
that this value can be met. 
 
3.1.4.2 Derivation of intake levels for morphine in poppy seeds 
Aside from the genotoxicity findings, what is important for the establishment of tolerable in-
take levels of morphine in food is the threshold dose upwards of which relevant health effects 
are to be expected in humans. A threshold dose of this kind cannot, however, be defined on 
the basis of existing data because of the diverse pharmacological and toxicological effects of 
morphine and the major variations in individual sensitivity (cf. 3.1.2.1.1.1). Nor is this de-
scribed in the literature. What renders this situation even more difficult is the fact that data 
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from pharmaceutical applications of morphine can only be transferred to a limited degree to 
the consumption of poppy seeds as healthy test persons react differently from pain patients 
with respect to toxicologically relevant morphine effects (3.1.2.1.1.2), dose response rela-
tionships in patients treated with morphine can be shifted to higher dose ranges because of 
tolerance development and opioid-naive healthy individuals are more sensitive to morphine 
than pain patients undergoing opiate treatment (3.1.2.1.1.4). Furthermore, morphine is nor-
mally given to seriously ill individuals who may react differently from healthy individuals to 
morphine because of specific disease-related impairments. 
 
The pharmacological scientific literature shows that in adults a single oral effective dose of 
morphine is normally given as 7.6 mg/person (equivalent to 127 µg/kg body weight for an 
adult weighing 60 kg) (42) and in the lowest case as 1.9 mg/person (equivalent to 31.7 µg/kg 
body weight for an adult weighing 60 kg) (39) (3.1.2.1.1.1). At these therapeutic doses in line 
with the comments under 3.1.2.1.1.2 healthy individuals can be expected to develop at least 
nausea, retching, light-headedness, dizziness, difficulties in carrying out intellectual tasks, 
apathy and reduced physical activity as well as other adverse reactions to normal therapy 
doses (cf. 3.1.2.1.1.5) like dry mouth, obstipation, sleepiness and headache. In principle, 
variations in individual sensitivity must be taken into account. Psychomotor restrictions, 
which can impede the ability to drive a car or operate machinery, must be considered. They 
can be worsened by the parallel consumption of alcohol or pharmaceuticals affecting the 
central nervous system (cf. 3.1.2.1.1.5). 
 
In line with this, forensic studies by Westphal et al. (29, 30) showed that morphine intakes of 
11.4 mg (equivalent to 135 to 191 µg/kg body weight) from the matrix of poppy seeds also 
led to the above-listed symptoms typical for morphine (cf. 3.1.2.2.1). As only two test persons 
with lower morphine intakes were tested, these investigations do not permit any statements 
about a threshold dose. Whether doubt should be cast on the symptoms (listlessness, short-
age of power, sleepiness) described by one of the two test persons, who had ingested 2.9 
mg morphine (equivalent to 40.2 µg/kg body weight) – as suggested by the authors - cannot 
be assessed here. Furthermore, it is uncertain whether a medical examination, which did not 
take place, would have revealed further effects. 
 
Therefore, regarding the central and peripheral adverse reactions, the lowest effective dose 
indicated for oral drug formulations for morphine of 1.9 mg (equivalent to 31.7 µg/kg body 
weight at a body weight of 60 kg) also seems to be transferable to the matrix of poppy seeds. 
Given 
 
• the existing uncertainty concerning the threshold doses of health-relevant effects, in par-
ticular psychomotor effects, 
 
• possible interactions e.g. with other opium alkaloids in poppy seeds, central nervous 
pharmaceutics and alcohol, 
 
• the uncertainty arising from the above situation for safety at the workplace and on the 
road, 
 
• the expected interindividual variations in sensitivity and 
 
• higher sensitivity in older people and in the case of numerous clinical pictures 
 
according to common scientific practice the tolerable intake level should be at least ten times 
lower than the indicated lowest effective dose. The guidance values derived from this intake 
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for morphine in poppy seeds would, however, be so low that only a few batches at the pre-
sent time could comply with them. As the indication of a "tolerable intake level" does not ap-
pear to be justified either given the genotoxic potential of morphine, a "provisional daily upper 
intake level" is recommended for the time being which is five times lower than the lowest 
effective dose. This appears justifiable when accompanied by recommendations to consum-
ers to refrain from regular and excessive consumption of poppy seeds, and to manufacturers 
to exhaust all technological possibilities in order to reduce morphine contents in poppy seeds 
as far as possible. The "provisional daily upper intake level" is 6.3 µg/kg body weight. It indi-
cates the daily dose of morphine from poppy seed containing foods which a person referred 
to kg body weight should not exceed during one meal or several meals spread over the day. 
It applies to adults and children (the intake of 6.3 µg/kg body weight is 13 times lower than 
the lowest known oral single dose for children of 83 µg morphine/kg body weight) (cf. 
3.1.2.1.1.1). 
 
3.1.4.3 Derivation of provisional guidance values for morphine in poppy seeds 
In Chapter 3.1.3 “Exposure to poppy seeds" it was estimated how many poppy seeds an 
adult/a child could eat during a meal per day in the case of high or worst case consumption. 
The guidance values are determined on the basis of the estimated amount of 100 g poppy 
seeds eaten by adults which is regarded as a high level of consumption. If one takes the pro-
visional daily upper intake level of 6.3 µg morphine/kg body weight/day established in Chap-
ter 3.1.4.2 as the basis, then according to this an adult weighing 60 kg who eats 100 g poppy 
seeds should not ingest more than 0.38 mg morphine. This leads to a provisional guidance 
value of 4 µg morphine/g for poppy seeds. Based on the consumption of 150 g poppy seeds 
assumed in the worst case, this means a maximum intake of 0.6 mg morphine which is 3.2 
times lower than the lowest therapeutic dose. In the case of sensitive individuals, too, the 
occurrence of central or peripheral effects are considered unlikely under these circum-
stances. 
 
An exposure of maximum 0.2 mg morphine is calculated for children if the provisional guid-
ance value is complied with using the example of a 5-year-old girl weighing 14.6 kg (5th per-
centile) (50) who has a "high consumption" of 50 g poppy seeds. The lowest known thera-
peutic dose for children of 83 µg morphine/kg body weight, i.e. 1.21 mg for a girl weighing 
14.6 kg, is therefore undercut by factor 6.1. Based on the worst-case assumption of 75 g 
poppy seeds, this leads for the same child to a maximum intake of 0.3 mg morphine which 
has a margin of factor 4 to the lowest therapeutic dose. On these conditions, too, central or 
peripheral morphine effects are not to be expected. 
 
Given the genotoxic potential of morphine (cf. 3.1.2.1.1.6), manufacturers are called on to 
take the appropriate steps to reduce the morphine levels in poppy seeds below the above-
mentioned provisional guidance values. The regular and excessive consumption of foods 
with a high poppy seed content is advised against particularly during pregnancy. 
 
Interim regulation 
 
Since at least half of the samples examined are below the provisional guidance value of 4 µg 
morphine/g according to the results of Thevis et al. (13, Table 1) and Trafkowski et al. (15, 
Table 2), this value seems feasible. The most recent measurements of the Bavarian LGL on 
morphine levels in poppy seeds (Table 3) identified a trend towards far higher values and 
only 4 out of 48 sample had values ≤ 4 µg morphine/g. Hence, it must be assumed that the 
provisional guidance value of 4 µg morphine/g is not currently being complied with by the 
majority of poppy seed batches. Nor can it be achieved through cleaning and offcut. In this 
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situation, one possible management option, until the desired measures to reduce morphine 
contents in poppy seeds have taken effect (cf. 3.2), is compliance with the "provisional daily 
upper intake levels" for morphine through additional interim guidance values which are tied to 
the declaration of consumption restrictions on poppy seed packaging. Similar measures 
could be considered for processing plants. This presupposes that manufacturers determine 
morphine levels in each poppy seed batch.  
 
a) Poppy seeds in the retail trade for direct sale to the consumer 
 
A maximum value of 20 µg morphine/g is recommended as the "interim guidance value with 
consumption restrictions", Depending on the morphine level measured, the maximum daily 
portions given in Table 10 would result. 
 
 
Table 10: Interim regulation: proposal for the declaration of maximum daily portions of poppy 
seeds depending on morphine level 
 
Morphine level of poppy seeds 
µg/g 
Maximum daily portion of poppy seeds to be de-
clared 
< 4 No declaration 
>  4 up to 8 50 g 
>  8 – 12 30 g 
> 12 – 16 25 g 
> 16 – 20 20 g 
 
b) Poppy seeds for processing plants 
 
Here, too, a maximum value of 20 µg morphine/g is recommended as the "interim guidance 
value with consumption restrictions". The information in Table 11 is based on the assumption 
that no more than 4 portions of poppy seed-containing foods (poppy seed rolls, poppy seed 
cake) should be consumed usually per day. Consequently, one portion should only contain 
one-quarter of the "provisional daily upper intake level" of 0.38 mg morphine, i.e. 95 µg mor-
phine for an adult weighing 60 kg. It is recommended that for manufacturers of ready-to-eat 
foods the maximum poppy seed amount per portion for each poppy seed batch, which will 
depend on the morphine content of the batch, is indicated (cf. Table 11). 
 
Table 11: Instructions for manufacturers of ready-to-eat foods concerning the levels of poppy 
seeds per portion which may not be exceeded depending on the morphine level  
 
Morphine level of poppy seeds 
µg/g 
Instructions for the production plant of the ready-
to-eat food 
< 4 No information 
> 4 – 12 Maximum poppy seed amount per ready-to-eat 
portion: 8 g 
> 12 – 20 Maximum poppy seed amount per ready-to-eat 
portion: 5 g 
 
3.1.4.4 Forensic aspects 
In case of compliance with the provisional daily upper intake level, even worst case morphine 
intakes (150 g poppy seeds) would still be considerably lower than the morphine dose of 14 
mg indicated by Westphal et al. (33). When it is exceeded it can be assumed that the as-
sessment value of 10 ng/ml free morphine in serum proposed by the "Grenzwertkommission" 
will be reached. The reaching of this value during traffic controls could thus no longer be at-
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tributed to the consumption of poppy seed-containing foods as long as they complied with 
this guidance value. The same would probably apply to "false positive" findings after the con-
sumption of poppy seed-containing foods during doping controls in sports medicine which 
are not discussed here (36, 37). 
 
3.1.4.5 Abuse aspect 
It can be assumed that poppy seeds, whose morphine content corresponds to the guidance 
value, are not likely to be misused for drug purposes since the morphine yields from the ex-
traction processes described (cf. 3.1.2.2.2) are likely to be small. 
 
3.1.4.6. Summary fundamental assessment 
Poppy seeds are considered as foods which, according to scientific knowledge, themselves 
only contain very low levels of morphine (cf. 3.1.1.1). They are, therefore, exempted from the 
Narcotics Act (BtMG) (cf. 3.1.1.2). However, according to actual data normal consumption 
habits of poppy seeds could lead to an intake of the opiate morphine – obviously through 
contamination or the selection of false manufacturing conditions, respectively, (cf. 3.1.1.4) –
which is on a par with therapeutic effective doses which are used to treat severe pain and 
are governed by the Narcotics Act. This situation is completely unacceptable. If morphine or 
opium components adhering to the seeds reach the market in this way, the question must be 
asked whether this does not, in fact, constitute an infringement of the Narcotics Act (BtMG). 
This also seems likely given the suitability of the seeds for abusive drugs production (cf. 
3.1.2.2). From this obligatory results that under aspects of health assessment the situation is 
unacceptable within the framework of food legislation, too. Hence the regional authorities had 
already voiced complaints pursuant Article 14 paras 2a and 4 Regulation (EC) 178/2002. In 
order to have a clear basis for decision when poppy seeds batches showing borderline mor-
phine contents have to be judged, it is recommended that the proposed provisional guidance 
for morphine should be applied. Every possible effort should be made to reduce the levels of 
all pharmacologically active opium alkaloids in poppy seeds to the lowest technically achiev-
able minimum. It is recommended that guidance values be established on this basis too for 
codeine, noscapine, papaverine and thebaine. For this purpose, as far as the current data 
situation permits, provisional guidance values are indicated which are deemed acceptable 
from the health angle. 
 
3.2 Action framework/measures 
 
- It is recommended that each imported batch of poppy seeds currently placed on the mar-
ket, be examined by manufacturers for its morphine content. 
 
- Targeted efforts are deemed necessary in order to reduce the contents of pharmacologi-
cally active opium alkaloids, in particular morphine, to the technically feasible minimum. 
Research into the causes is deemed necessary. It is proposed that the reasons for high 
morphine contamination be identified by tracing the source (geographical origin, botanical 
origin/choice of varieties, cultivation conditions, climatic influence, harvest year, harvest-
ing technique, cleaning conditions). Important data are expected when the above-
mentioned parameters are compared between countries which primarily export products 
with a low level of contamination (e.g. Turkey) and those which supply batches with a 
high level of contamination (e.g. Australia). 
 
- Consideration should be given to the aspects compiled in Chapter 3.1.1.4. For instance, it 
should be examined what successes could be achieved in reducing morphine levels by 
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improving harvesting and cleaning methods (e.g. removal of immature capsules, opening 
of capsules by hand, introduction of washing steps). Furthermore, it should be clarified 
whether poppy seeds with a high alkaloid contamination primarily originate from varieties 
of Papaver somniferum which are used because of high alkaloid production in parallel to 
alkaloid or opium harvesting. 
 
- With reference to the low morphine content (3.5 µg/g) of seeds of the low morphine vari-
ety "Przemko" (cf. 3.1.1.3), it is recommended that the selection and cultivation of poppy 
varieties with a low morphine content be promoted. More information on this may be 
available from Austria (6) (cf. 3.1.1.1). 
 
- It is recommended that official food control authorities be asked to carry out controls of 
poppy seed samples in all federal states (monitoring). 
 
- It is recommended that standardised determination methods be elaborated for opium 
alkaloids from poppy seeds in order to guarantee the comparability of measurements 
taken. 
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